<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85345</article-id><article-id pub-id-type="doi">10.7554/eLife.85345</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Defects in lipid homeostasis reflect the function of TANGO2 in phospholipid and neutral lipid metabolism</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-300206"><name><surname>Lujan</surname><given-names>Agustin Leonardo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4906-6951</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5404"><name><surname>Foresti</surname><given-names>Ombretta</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6878-0395</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311414"><name><surname>Sugden</surname><given-names>Conor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40487"><name><surname>Brouwers</surname><given-names>Nathalie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9808-9394</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300513"><name><surname>Farre</surname><given-names>Alex Mateo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300514"><name><surname>Vignoli</surname><given-names>Alessio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7131-2915</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311412"><name><surname>Azamian</surname><given-names>Mahshid</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311413"><name><surname>Turner</surname><given-names>Alicia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300515"><name><surname>Wojnacki</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1133"><name><surname>Malhotra</surname><given-names>Vivek</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6198-7943</contrib-id><email>vivek.malhotra@crg.eu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03kpps236</institution-id><institution>Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Center for Cell and Gene Therapy, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04n0g0b29</institution-id><institution>Universitat Pompeu Fabra (UPF)</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0371hy230</institution-id><institution>ICREA</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85345</elocation-id><history><date date-type="received" iso-8601-date="2022-12-03"><day>03</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-22"><day>22</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-11-05"><day>05</day><month>11</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.11.05.515282"/></event></pub-history><permissions><copyright-statement>© 2023, Lujan et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Lujan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85345-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85345-figures-v2.pdf"/><abstract><p>We show that TANGO2 in mammalian cells localizes predominantly to mitochondria and partially at mitochondria sites juxtaposed to lipid droplets (LDs) and the endoplasmic reticulum. HepG2 cells and fibroblasts of patients lacking TANGO2 exhibit enlarged LDs. Quantitative lipidomics revealed a marked increase in lysophosphatidic acid (LPA) and a concomitant decrease in its biosynthetic precursor phosphatidic acid (PA). These changes were exacerbated in nutrient-starved cells. Based on our data, we suggest that TANGO2 function is linked to acyl-CoA metabolism, which is necessary for the acylation of LPA to generate PA. The defect in acyl-CoA availability impacts the metabolism of many other fatty acids, generates high levels of reactive oxygen species, and promotes lipid peroxidation. We suggest that the increased size of LDs is a combination of enrichment in peroxidized lipids and a defect in their catabolism. Our findings help explain the physiological consequence of mutations in TANGO2 that induce acute metabolic crises, including rhabdomyolysis, cardiomyopathy, and cardiac arrhythmias, often leading to fatality upon starvation and stress.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>TANGO2</kwd><kwd>lipid droplet</kwd><kwd>reactive oxygen species</kwd><kwd>acyl-CoA</kwd><kwd>lysophosphatidic acid</kwd><kwd>lipid peroxidation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010198</institution-id><institution>Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España</institution></institution-wrap></funding-source><award-id>PID2019-105518GB-I00</award-id><principal-award-recipient><name><surname>Malhotra</surname><given-names>Vivek</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>ERC-2020-SyG-Proposal No. 951146</award-id><principal-award-recipient><name><surname>Malhotra</surname><given-names>Vivek</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004410</institution-id><institution>European Molecular Biology Organization</institution></institution-wrap></funding-source><award-id>EMBO ALTF 659-2021</award-id><principal-award-recipient><name><surname>Lujan</surname><given-names>Agustin Leonardo</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>H2020-MSCA-IF-2019-894115</award-id><principal-award-recipient><name><surname>Wojnacki</surname><given-names>Jose</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovación</institution></institution-wrap></funding-source><award-id>RYC-2016-20919</award-id><principal-award-recipient><name><surname>Foresti</surname><given-names>Ombretta</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>TANGO2 emerges as a key regulator of fatty acid metabolism by likely affecting acyl-CoA production and utilization.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In 2006, we reported a collection of new genes required for transport and organization of the Golgi complex in <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib2">Bard et al., 2006</xref>).⁠ These genes, monikered TANGO, include TANGO1, a transmembrane protein required for the organization of endoplasmic reticulum (ER) exit sites where it collects bulky molecules like collagens and stabilizes transient inter-organelle tunnels for their export to the next compartment of the secretory pathway (<xref ref-type="bibr" rid="bib33">Raote and Malhotra, 2021</xref>).</p><p>TANGO2, a gene unrelated to TANGO1, lacks a transmembrane domain and is reported to be cytosolic and also localized to mitochondria (<xref ref-type="bibr" rid="bib19">Jennions et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Milev et al., 2021</xref>). TANGO2 affects ER-to-Golgi transport and mitochondria physiology; however, its precise role in these compartments is unknown (<xref ref-type="bibr" rid="bib26">Mingirulli et al., 2020</xref>; <xref ref-type="bibr" rid="bib4">Bérat et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Milev et al., 2021</xref>)⁠. Mutations in TANGO2 result in metabolic encephalopathy and arrhythmias and these conditions are exacerbated upon nutrient starvation, often leading to fatality (<xref ref-type="bibr" rid="bib20">Kremer et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">Lalani et al., 2016</xref>)⁠. What is the physiological role of TANGO2, and how do mutations in TANGO2 lead to fatality in conditions of starvation?</p><p>We show here that TANGO2 in mammalian cells localizes predominantly to mitochondria, but also partially to sites where the ER and lipid droplets (LDs) are juxtaposed to mitochondria. Knockdown of TANGO2 increased the size of LDs and elevated intracellular reactive oxygen species (ROS) levels. Mass spectrometric quantification of cellular lipids revealed that TANGO2-deficient cells exhibited markedly high lysophosphatidic acid (LPA) and low levels of phosphatidic acid (PA). These cells were also highly reduced in cardiolipin (CL), which is ordinarily produced from PA. Moreover, changes in these cellular properties were further exacerbated in cells cultured in low-nutrient media. Many of these features match properties in cells derived from patients with mutations in TANGO2. Based on our data, we propose that TANGO2 functions in lipid homeostasis at the level of acyl-CoA metabolism, and defects in lipid metabolism are the main cause of starvation-induced acute rhabdomyolysis, cardiomyopathy, and cardiac arrhythmias.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>TANGO2 localizes predominantly to the mitochondria and transiently to LDs and ER</title><p>In humans, six isoforms of TANGO2 are produced by alternative splicing. The TANGO2-1 (TNG2_HUMAN·Q6ICL3-1) and TANGO2-2 (TNG2_HUMAN·Q6ICL3-2) isoforms are most similar to their orthologs, such as hrg-9 in worms, ygr127w in yeast, and tango2 in zebrafish (<xref ref-type="fig" rid="fig1">Figure 1A, B</xref>). It is important to note that the anti-Tango2 antibody we have used here recognizes both isoforms in human cells, and tagged versions of both isoforms show the same intracellular location (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). As shown in the following sections, siRNA-based depletion affects all isoforms. Therefore, the effect of TANGO2 depletion on cell physiology is a result of reduction in the levels of all isoforms.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>TANGO2 orthologs.</title><p>(<bold>A</bold>) In silico sequence alignment of TANGO2 orthologs in human (<italic>H. sapiens</italic>), zebrafish (<italic>D. rerio</italic>), fruit fly (<italic>D. melanogaster</italic>), worm (<italic>C. elegans</italic>), and yeast (<italic>S. cerevisiae</italic>) using T-COFFEE software. The transitive consistency score (TCS) color code indicates the agreement between the library and the considered alignment. The TCS scale goes from blue (less consistent) to dark pink (high reliability and more accurate agreement) brick regions. The color line (cons?) below the alignment indicates the consensus score of every column. Residue numbering is based on the full length of the human TANGO2 protein (TNG2_HUMAN·Q6ICL3). (<bold>B</bold>) Multiple sequence alignment (MSA) of each human TANGO2 isoform with species orthologs. The TCS identifies the most correct alignment positions in MSA, the Identity evaluates the sequence function, and the Coverage describes the average number of reads that align to known reference bases.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig1-v2.tif"/></fig><p>Previous published data showed conflicting results on the intracellular location of TANGO2 (<xref ref-type="bibr" rid="bib19">Jennions et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Heiman et al., 2022</xref>; <xref ref-type="bibr" rid="bib25">Milev et al., 2021</xref>)⁠. Unfortunately, the commercially anti-TANGO2 antibodies are not suitable for immunofluorescence analysis. Therefore, we monitored the location of TANGO2 distribution dynamically in living cells. We generated C-terminally tagged version of Tango2 by in frame fusion with either mScarlet (TANGO2.Iso1-mScarlet) or EGFP (TANGO2.Iso1-EGFP). By transient transfections in HepG2 cells, we co-expressed these forms of TANGO2 with fluorescent markers of various subcellular organelles including, mitochondria (Mito-mTurquoise), ER (ER-mTurquoise), peroxisomes (Peroxisome-mTurquoise), and LDs (GPAT4-mNeonGreen). All images were acquired by live-cell confocal time-lapse microscopy to avoid fixation artefacts. We observed high colocalization (Pearson coefficient, <italic>r</italic> = 0.88) between TANGO2 and the mitochondria marker. TANGO2 was also enriched at sites of mitochondria closely juxtaposed to ER and LDs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). To further ascertain the location of TANGO2, we monitoried its intracellular locale with respect to ER and LDs in fixed cells. HepG2 cells were co-transfected with TANGO2-mScarlet and VAPB-NeonGreen – a protein located in the ER membrane and in the mitochondria-associated membrane sites (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), or with the LD marker GPAT4-NeonGreen (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). We observed TANGO2-Scarlet and the specific markers of ER and LDs in close position in <italic>XY</italic>, <italic>XZ</italic>, and <italic>YZ</italic> planes.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TANGO2 location in HepG2 cells.</title><p>(<bold>A</bold>) Cells expressing TANGO2.Iso1-mScarlet co-transfected with Mitochondria-pmTurquoise2 (Mito-mTurquoise), ER-pmTurquoise2 (ER-mTurquoise), Peroxisome-SKL-mTurquoise2 (Peroxisome-mTurquoise), or GPAT4-hairpin-mNeonGreen (GPAT4-mNeonGreen) to detect lipid droplets. The yellow color indicates colocalization between both red and green labels. Pearson coefficient (<italic>r</italic>) was calculated with the coloc2 plugin in ImageJ software. Images are representative of three independent experiments. Scale bars = 10 µm. (<bold>B–D</bold>) HeLa cells were transfected with TANGO2.mScarlet, fixed, and incubated with anti-Tom20 followed by Alexa 633 secondary antibodies. (<bold>B</bold>) Representative image of the fluorescence intensity in the acceptor (upper panels) and donor (bottom panels) channels before (left panels) and after photobleaching (right panels) of the acceptor. (<bold>C</bold>) Representative map of Förster resonance energy transfer (FRET) efficiency calculated from the donor fluorescence intensity as described in Materials and methods. (<bold>D</bold>) Quantification of the increase in fluorescence intensity of the donor channel (TANGO2.mScarlet) after photobleaching (<italic>n</italic> = 15 cells). R. F. U. means relative fluorescence units.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Intact expressed tagged TANGO2 is in close proximity to endoplasmic reticulum (ER) and lipid droplets (LDs).</title><p>(<bold>A</bold>) HepG2 cells expressing TANGO2.Iso1-mScarlet and co-transfected with VAP-B.mNenonGreen to detect ER membranes. The dotted line in the <italic>XY</italic> plane shows the slice projected in the <italic>ZY</italic> and <italic>XZ</italic> axes. The yellow color indicates colocalization between red and green labels in the different projections. Scale bars = 10 µm. (<bold>B</bold>) HepG2 cells expressing TANGO2.Iso1-mScarlet and co-transfected with GPAT4-hairpin.mNenonGreen to detect LDs (LDs do not have a membrane). The dotted line in the <italic>XY</italic> plane shows the slice projected in the <italic>ZY</italic> and <italic>XZ</italic> axes. The yellow color indicates colocalization between red and green labels in the different projections. Scale bars = 10 µm. (<bold>C</bold>) TANGO2.Iso1-EGFP HepG2 stable cells were transiently transfected with TANGO2.Iso1-mScarlet (red), and labeled with Hoechst (blue). Merge shows all overlapping channels. (<bold>D</bold>) TANGO2.Iso1-EGFP (green) HepG2 stable cell was labeled with Hoechst (blue). (<bold>E</bold>) Immunoblot analysis of TANGO2.Iso1-EGFP HepG2 stable cell line incubated with anti-GFP and anti-β-actin. Anti-β-actin was used as a loading control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To confirm the precise topology of TANGO2-mScarlet in the mitochondria membrane, we evaluated the proximity between TANGO2 and Tom20 – a protein marker of the outer mitochondrial membrane (OMM) – by Förster resonance energy transfer (FRET) microscopy in fixed cells. This procedure analyzes the radiation energy transfer from an excited fluorescent molecule (called the donor) to an acceptor molecule; this occurs when both molecules are within a range of 1–10 nm from each other (<xref ref-type="bibr" rid="bib6">Broussard et al., 2013</xref>). To explore the proximity of TANGO2 toTom20, HepG2 cells were transfected with TANGO2.mScarlet (red), fixed, and stained with anti-Tom20 antibody (green) followed by Alexa 633 secondary antibody. After photobleaching (white square) of Alexa 633 we observed a significant increase (p=0.0002) in mScarlet-fluorescence intensity compared to an unbleached region (yellow square), confirming an FRET signal (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>).</p><p>To avoid potential artefacts from an uneven or abnormal protein expression by transient transfection, we generated stable cell lines expressing low levels of the C-terminally EGFP-tagged TANGO2 using lentiviral infection (<xref ref-type="bibr" rid="bib40">Tandon et al., 2018</xref>)⁠. Live imaging of stable cell lines revealed that TANGO2-GFP localizes predominantly to mitochondria (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). We also observed a diffuse cytosolic staining (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). To check whether TANGO2-EGFP is cleaved in our experimental conditions giving rise to different forms, we verified the size of expressed construct by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) followed by western blotting with anti-GFP antibody (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). This revealed a single band that matches the expected molecular weight of EGFP-tagged TANGO2.</p><p>It is therefore reasonable to conclude that despite lacking a transmembrane domain, TANGO2 is attached predominantly to the mitochondrial outer membrane and at sites of mitochondria that are juxtaposed to the ER and the LDs. TANGO2 likely cycles between the cytoplasm and the membrane. The mechanism of how TANGO2 is recruited to the membrane is not known.</p></sec><sec id="s2-2"><title>TANGO2-lacking cells contain larger LDs</title><p>As shown above, TANGO2 frequently appears at sites that are marked by LDs. This prompted us to test whether cells lacking TANGO2 are affected in any aspect of LDs. We silenced TANGO2 (siTANGO2) by standard siRNA-based procedures. A control was generated with non-targeting siRNA and described henceforth as Mock. The silencing procedure reduced TANGO2 levels by ~45% after one round of siRNA transfection. However, after two sequential rounds of transfection, a ~75% reduction in TANGO2 levels was evident (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). We have used double sequential transfections to reduce TANGO2 levels in all experiments that follow (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Mock HepG2 cells and TANGO2-depleted cells were cultured in medium (Dulbecco’s Modified Eagle’s Medium, DMEM) supplemented with 10% fetal bovine serum (FBS) (DMEM complete) or OptiMEM without FBS (starvation) for 4 hr. Cells were then incubated with membrane permeant neutral lipid marker HCS LipidTOX Deep Red (red) and the DNA marker Hoechst-33342 (blue) for 30 min at 37°C followed by live-cell imaging. LDs were consistently larger in TANGO2-depleted cells compared to mock cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, left panel). Moreover, nutrient-deprived TANGO2-depleted cells (Starvation; <xref ref-type="fig" rid="fig3">Figure 3A</xref>, right panel) had even larger LDs. To confirm that these structures are indeed LDs, TANGO2-depleted HepG2 cells were fixed and visualized with an antibody to the LD-resident protein ADRP (red). Nuclear DNA in these cells was labeled with 4',6-diamidino-2-phenylindole (DAPI; blue). There was indeed an increase in the size of ADRP-containing LDs upon depletion of TANGO2 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We developed a macro for ImageJ Software, to quantify this increased retention of neutral lipids upon depletion of TANGO2. This procedure analyzes <italic>z</italic>-stack images to determine the number and volume of each LipidTOX-positive particle. Five samples were used for each condition, with a total of 67 Mock cells and 75 TANGO2-depleted cells, respectively. As shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>, total volume of LDs per cell (panel C) and the volume of each LD (panel D) were significantly higher in TANGO2 depleted compared to the Mock cells (p = 0.0005 and p = 0.002, respectively). However, the number of LDs in each cell remains the same regardless of the TANGO2 levels (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Therefore, the increase in size is not caused by fusion of smaller LDs under these experimental conditions. To further analyze the effect of TANGO2 on LDs size, we added 120 nM Oleic acid (OA), which is known to potentiate LD formation, at 37°C for 6 hr to TANGO2 transiently depleted HepG2 cells (Mock vs. siTANGO2) and fibroblasts from TANGO2 deficiency disorder (TDD) donors (WT vs. TAN043). Changes in the total volume of LDs were evaluated by fluorescence intensity (FI) of allophycocyanin (APC) corresponding to HCS LipidTOX with flow cytometry (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Three independent experiments were analyzed for each condition in triplicate. The loss of TANGO2 revealed a significant increase in total LDs volume compared to Mock HepG2 cells (<xref ref-type="fig" rid="fig3">Figure 3F</xref>) or wild-type fibroblasts (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). To reveal the cause for increased volume of LDs we analyzed their metabolism. To explore LD biogenesis in WT and TAN043 fibroblast, we generated three independent medium conditions of DMEM complete (control), adding 120 nM OA at 37°C for 6 hr in DMEM complete (+OA), or adding 120 nM OA at 37°C for 6 hr with the lipolysis inhibitor diethylumbelliferyl phosphate (DEUP) in DMEM complete (+OA + DEUP) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). The inhibition of lipolysis in complete-medium conditions revealed a greater increase of LipidTOX marker in TANGO2-depleted fibroblasts compared to WT (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). This result suggests a more prominent activation of the LD biogenesis in TANGO2-lacking fibroblasts. To test the effect on LD consumption, we added 240 nM OA at 37°C for 12 hr in DMEM complete medium. We then changed the supplemented OA medium with fresh-complete medium including DEUP to synchronize lipolysis initiation (+OA + DEUP), nutrient-free medium to activate starvation (+OA + Starvation) or nutrient-free medium with DEUP to block lipolysis (+OA + Starvation + DEUP) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Fasting induction demonstrated a drastic alteration of the lipolytic pathway in TANGO2-depleted fibroblasts compared to WT fibroblasts (<xref ref-type="fig" rid="fig3">Figure 3I</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>TANGO2 depletion affects lipid droplets’ (LDs) size, biogenesis, and lipolysis.</title><p>(<bold>A</bold>) Confocal images of HCS LipidTOX Deep Red marker (red) and Hoechst-33342 (blue) in mock (top) and TANGO2-depleted (bottom) HepG2 cells cultured in control conditions (Dulbecco’s Modified Eagle’s Medium [DMEM] complete; left panel) or starved of nutrients (starvation; right panel). Scale bars = 10 µm. (<bold>B</bold>) Mock (top) and TANGO2-depleted (bottom) cells in control conditions were fixed and incubated with anti-ADRP (red) and DAPI (blue). Scale bars = 10 µm. (<bold>C–E</bold>) Quantification of LDs in mock (<italic>n</italic> = 67 cells) and TANGO2-depleted (<italic>n</italic> = 75 cells) cells in five samples for each condition by an ImageJ macro developed in our laboratory (open code access in Materials and methods). (<bold>C</bold>) Total volume of LDs present per cell. (<bold>D</bold>) Volume of each LD in a cell. (<bold>E</bold>) Number of LDs per cell. (<bold>F, G</bold>) Quantification of total LD volume in DMEM complete medium (control) and supplemented with 120 nM Oleic acid (+OA) using HCS LipidTOX Deep Red marker by flow cytometry. (<bold>F</bold>) Mean fluorescence intensity (mean FI) of allophycocyanin (APC) detected in Mock and TANGO2-depleted HepG2 cells in three different samples of each condition. (<bold>G</bold>) Mean fluorescence intensity (mean FI) of APC detected in wild-type (WT) and TANGO2-deficient disease (TAN043) fibroblasts in three different samples of each condition. (<bold>H</bold>) Quantification of total LD’s volume in DMEM complete medium (control), supplemented with 120 nM Oleic acid (+OA), or supplemented with 120 nM OA and 500 µM diethylumbelliferyl phosphate (DEUP) in WT and TAN043 fibroblasts by flow cytometry. (<bold>I</bold>) Quantification of total LD volume after supplementation with 240 nM OA for 12 hr, washed and starved for 5 hr with DEUP in WT and TAN043 fibroblasts by flow cytometry. Images and graphs are representatives of three independent experiments. In graphs, boxes and bars are the mean ± standard deviation (SD). A.U. means arbitrary units.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Depletion of TANGO2 in HepG2 cells.</title><p>(<bold>A</bold>) Immunoblot analysis of HepG2 wild-type (L2–3) cells silenced after one (L4–5) or two (L6–7) rounds of TANGO2 siRNA transfection. (<bold>B</bold>) Double siRNA transfection scheme used to reduce endogenous TANGO2 levels. (<bold>C</bold>) Mock and TANGO2-depleted HepG2 cells maintained in control conditions or with 120 nM Oleic acid (OA), and incubated with HCS LipidTOX Deep Red for 30 min before flow cytometry analysis. Neutral lipids were detected by measuring the fluorescence intensity of allophycocyanin (APC). (<bold>D</bold>) Scheme of the method used for the neutral lipids biogenesis analysis in WT and TAN043 fibroblasts. (<bold>E</bold>) Scheme of the method used for the neutral lipids lipolysis analysis induced by nutrient fasting in WT and TAN043 fibroblasts.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Altogether, depletion of TANGO2 displays substantial enlargement of LDs by a combination of increased biogenesis and a pronounced defect in lipolysis.</p></sec><sec id="s2-3"><title>TANGO2 depletion affects the quantities of specific lipids</title><p>A change in the size of LDs in TANGO2-depleted cells prompted us to analyze changes in the cellular lipid composition. Also of note is the observation that patients with TANGO2 deficiency suffer metabolic crises upon fasting, which suggests an impairment in lipid metabolism. Mock cells (Mock), TANGO2-depleted cells (siTANGO2), starved mock cells (Starvation), and starved TANGO2-depleted cells (siTANGO2 starvation) were analyzed in triplicates to quantitate their total lipid composition (Lipotype GmbH). We used the mole percent fraction (molp) analyses because that enables comparisons between the lipidomic profiles of different conditions, disregarding the absolute amount of lipids (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). However, we also report the absolute levels of lipids in our conditions (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B, C</xref>).</p><p>First, to monitor the effect of physiological starvation, we compared samples of mock cells under control and starvation conditions (<xref ref-type="fig" rid="fig4">Figure 4</xref>, left panel). Upon starvation, LPA levels are reduced, whereas phosphatidylcholine (PC), lysophosphoglycerol (LPG), phosphoglycerol (PG), and PA levels are notably increased (<xref ref-type="fig" rid="fig4">Figure 4</xref>, left panel). LPA is used to produce PA, which is a precursor of PG and mitochondria-specific CL.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Lipidomics of TANGO2-depleted cells for comparison with control and nutrient-starved cells.</title><p>(<bold>A</bold>) Relative change of lipid class according to different conditions: physiological starvation (left panel), TANGO2-depleted cells in control conditions (middle panel), and TANGO2-depleted cells upon nutrient starvation (right panel). (<bold>B</bold>) Quantification of lysophosphatidic acid (LPA) changes in mock and TANGO2-depleted cells expressed in mole percent (molp) fractions. (<bold>C</bold>) Quantification of phosphatidic acid (PA) changes in mock and TANGO2-depleted cells expressed in molp fractions. (<bold>D</bold>) Quantification of CL changes in mock and TANGO2-depleted cells expressed in molp fractions. Data are representative of three independent experiments. In graphs, boxes are the mean ± standard deviation (SD).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Absolute values comparison of lipids in HepG2 mock and TANGO2-depleted cells.</title><p>(<bold>A</bold>) Relative levels of lipids in mock and TANGO2-depleted cells in control and nutrient-starved conditions in mole percent fraction (molp). (<bold>B</bold>) Quantification of the absolute amount of lipids in mock and TANGO2-depleted cells in control and nutrient-starved conditions in pico-mole (pmol). (<bold>C</bold>) Quantification of the absolute amount of lysophosphatidic acid (LPA), phosphatidic acid (PA), and cardiolipin (CL) in mock and TANGO2-depleted cells in control and nutrient-starved conditions in pmol. In graphs, boxes are the mean ± standard deviation (SD).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig4-figsupp1-v2.tif"/></fig></fig-group><p>Secondly, to monitor the effect TANGO2 depletion, we compared samples of Mock and TANGO2-depleted cells grown in normal condition (<xref ref-type="fig" rid="fig4">Figure 4</xref>, middle panel). TANGO2-depleted cells show an increase in levels of LPA and reduction in PA and CL levels. There was also an increase in most lyso-phospholipids and a reduction in the corresponding phospholipids (<xref ref-type="fig" rid="fig4">Figure 4</xref>, middle panel).</p><p>Lastly, to monitor the combine effect of starvation and TANGO2 depletion, we compared starved TANGO2-depleted cells with mock starved cells (<xref ref-type="fig" rid="fig4">Figure 4</xref>, right panel). Importantly, starving TANGO2-depleted cells exhibited a further increase in LPA and decrease in PA levels (<xref ref-type="fig" rid="fig4">Figure 4</xref>, right panel). Moreover, in TANGO2-depleted cells, LPG levels are reduced and there is a dramatic reduction in PG levels. The levels of these two lipids are further reduced in early starvation. We suggest that when PA levels are low, the cells use LPG and PG to produce CL in starving TANGO2-depleted cells and this is the likely reason for the partial restoration of CL levels under these conditions. These data show that nutrient-starved TANGO2-depleted cells have a dramatic change in their LPA to PA ratio and there is a subsequent defect in the homeostasis of additional fatty acids.</p></sec><sec id="s2-4"><title>The loss of TANGO2 affects the levels of enzymes involved in the metabolism of phospholipids and neutral lipids</title><p>Changes in the lipid profiles of TANGO2-depleted cells led us to analyze enzymes involved in lipid metabolism. PA has a central role as precursor of all components synthesized in the phospholipid biosynthetic pathway. In short, the glycerol-3-phosphate acyltransferases (GPATs) located in the ER (GPAT3/4) and OMM (GPAT1/2) membranes, catalyze the conversion of glycerol-3-phosphate (G3P) to LPA, by transferring a saturated fatty acid from Acyl-CoA. Then, the family of 1-acyl-sn-glycerol-3-phosphate acyltransferases (AGPATs), with lysophosphatidic acid acyltransferase (LPAAT) enzymatic activity, promote addition of an unsaturated fatty acid from acyl-CoA to LPA to form PA. Once formed, PA can generate diacylglycerol (DAG) after dephosphorylation by PA phosphatase enzymes (LPINs), or can reconvert to LPA by the action of phospholipase A2 (PLA2).</p><p>The expression of 13 enzymes involved in the phospholipid biosynthetic pathway was measured in three independent experiments by reverse transcription quantitative polymerase chain reaction (RT-qPCR). RNA extraction was performed in Mock and TANGO2-depleted HepG2 cells in complete medium and starvation medium. For mRNA quantification, we used GAPDH as a reference gene in all conditions. RT-qPCR graphs showed the normalized mRNA expression of each enzyme in TANGO2-depleted cells compared to Mock cells in three independent experiments. These results revealed an increase in GPAT3 and AGPAT1 mRNA expression inTANGO2-depleted cells compared to Mock cells in both control and fasting conditions (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>). Interestingly, AGPAT3 mRNA expression was decreased in control conditions but significantly increased in a nutrient-free conditioned medium. Furthermore, AGPAT5 mRNA expression was significantly higher in control conditions but not in nutrient deprivation conditions. However, the opposite was seen for AGPAT2 mRNA expression. The overexpression of AGPAT1 and AGPAT3 enzymes should increase PA production, but TANGO2 deficiency showed a decrease in the PA lipid profile by lipidomic analysis (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Moreover, the increase in GPAT3 mRNA expression might contribute to LPA formation.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TANGO2 depletion impacts enzymes of lipid metabolism.</title><p>Reverse transcription quantitative polymerase chain reaction (RT-qPCR) analyses of TANGO2-depleted HepG2 cells compared to mock cells in normal (<bold>A</bold>) and starvation (<bold>B</bold>) conditions. Three biological repeats were performed for each condition. Values were normalized to GAPDH and graphed as log fold change relative to Mock cells of each condition. Statistical significance was determined using a simple unpaired Student’s <italic>t</italic>-test with subsequent Welch’s correction analysis between TANGO2-depleted and Mock cells. In graphs, boxes are the mean ± standard deviation (SD). A.U. means arbitrary units.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig5-v2.tif"/></fig><p>Although further enzymatic studies should explore their location and functional activity, these data suggest that decreased production of PA triggers mechanisms to re-establish the physiological levels of this essential component, but the lack of TANGO2 prevents this restorative mechanism.</p></sec><sec id="s2-5"><title>TANGO2-depleted cells exhibit increased ROS and lipid peroxidation</title><p>Given the location of TANGO2 to mitochondria and a previous report of increased mitochondria ROS in cells of patients with a TANGO2 deficiency (<xref ref-type="bibr" rid="bib15">Heiman et al., 2022</xref>)⁠, prompted us to test this feature in our experimental conditions. Mitochondria produce ROS at the inner mitochondria membrane during oxidative phosphorylation. ROS produced as a byproduct of ATP synthesis is useful for cells, but high levels of ROS, unless scavenged, are toxic. Mock HepG2 cells (Mock), TANGO2 transiently depleted cells (siTANGO2), wild-type human fibroblasts (WT), and TANGO2 knock-out cells from TDD patients (TAN043) in complete medium or starvation medium, were incubated for 20 min with CellROX Deep Red reagent to measure cellular ROS levels and MitoTracker Green to measure total mitochondria mass by flow cytometry analysis. Cell viability was measured by using CellTrace Calcein Green AM. DNA-specific DAPI was used to test that TANGO2 silencing did not induce cell death in our samples (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). To determine the total mitochondria mass, we analyzed the fluorescence intensity (FI) of fluorescein isothiocyanate (FITC) corresponding to MitoTracker Green for all samples by flow cytometry (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The statistical analysis shows the mean FI (MFI) of FITC in three independent experiments. The results reveal no significant difference in total mitochondria mass in TANGO2-depleted cells compared to controls (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). To measure ROS production in these experimental conditions, we analyzed differences in FI of APC corresponding to CellROX marker (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). The data show that depletion of TANGO2 significantly increased ROS levels, which are further elevated upon nutrient starvation (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). As we observed a significant difference in the mitochondria mass between fibroblasts from healthy and TDD donors, we analyzed ROS levels by the ratio between CellROX and MitoTracker markers. These results corroborate that TANGO2-lacking fibroblasts have higher ROS levels than WT fibroblasts (<xref ref-type="fig" rid="fig6">Figure 6E</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>TANGO2-depleted cells exhibit increased reactive oxygen species (ROS) levels and lipid peroxidation.</title><p>(<bold>A–D</bold>) Mock and TANGO2-depleted cells were incubated in control conditions (Dulbecco’s Modified Eagle’s Medium [DMEM] complete) or in a low-nutrient medium (Starvation) for 4 hr. Cells were incubated with CellROX Deep Red to detect ROS levels and MitoTracker Green to monitor mitochondria mass. (<bold>A</bold>) Mitochondria mass was detected by measuring the fluorescence intensity of fluorescein isothiocyanate (FITC) by flow cytometry. (<bold>B</bold>) The mean fluorescence intensity (Mean FI) of FITC was measured in three different samples of each condition. (<bold>C</bold>) Cellular ROS levels were detected by measuring the fluorescence intensity of allophycocyanin (APC) by flow cytometry. (<bold>D</bold>) The mean fluorescence intensity of APC was measured in three different samples of each condition. (<bold>E</bold>) Ratio between ROS levels (CellROX) and mitochondria mass (MitoTracker) was measured in WT and TAN043 fibroblasts by flow cytometry in three independent experiments. (<bold>F</bold>) Lipid peroxidation in HepG2 and fibroblasts was measured by detecting the mean fluorescence intensity change between PE and FITC spectral emissions by flow cytometry. (<bold>G</bold>) The fold change shows the ratio between reduced and oxidized lipid species in Mock and TANGO2-depleted HepG2 cells in the control and nutrient-free medium. (<bold>H</bold>) The fold change shows the ratio between reduced and oxidized lipid species in WT and TAN043 fibroblasts. In graphs, bars and boxes are the mean ± standard deviation (SD). A.U. means arbitrary units.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Cell viability of TANGO2-depleted cells.</title><p>Mock and TANGO2-depleted cells were incubated with CellTrace Calcein Green AM (fluorescein isothiocyanate, FITC) and DAPI (Pacific Blue-A) to determine cell viability by flow cytometry. Each dot in the dot plot graph represents one cell. Each dot in the column graph represents one of three independent experiments. A.U. means arbitrary units.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85345-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Since the increase in ROS damage cellular components such as DNA, proteins, and lipids, we analyzed the peroxidation state of lipids. HepG2 cells transiently depleted of TANGO2 (Mock vs. siTANGO2) and fibroblasts derived from TDD donors (WT vs. TAN043) were incubated for 30 min with an Image-iT Lipid Peroxidation kit, a sensitive fluorescent reporter for measuring total lipid peroxidation, by flow cytometry. In a reduced state, the maximal emission of the sensor is 591 nm, corresponding to the FI of Phycoerythrin (PE) (<xref ref-type="fig" rid="fig6">Figure 6F</xref>, left panel). Upon oxidation, the reagent shifts the fluorescence emission peak from ~590 to ~510 nm corresponding to the FI of FITC (<xref ref-type="fig" rid="fig6">Figure 6F</xref>, right panel). To determine lipid peroxidation, we analyzed the MFI ratio between PE and FITC for all samples (<xref ref-type="fig" rid="fig6">Figure 6G, H</xref>). The statistical analysis shows the fold change of reduced/oxidized lipids in three independent experiments. The results show that rise in ROS production provokes an increase in lipid peroxidation of TANGO2-depleted HepG2 cells (<xref ref-type="fig" rid="fig6">Figure 6G</xref>) and TAN043 human fibroblasts (<xref ref-type="fig" rid="fig6">Figure 6H</xref>).</p><p>Altogether, these data show that TANGO2 depletion causes unsaturated lipid peroxidation, which is known to alter lipid quality.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>TANGO2, a less studied protein from the TANGO collection, is gaining attention recently because of mutations in TANGO2 lead to severe pathologies (<xref ref-type="bibr" rid="bib4">Bérat et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Hoebeke et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">Powell et al., 2021</xref>; <xref ref-type="bibr" rid="bib35">Schymick et al., 2022</xref>)⁠⁠. Patients with mutations in TANGO2 exhibit defects in cardiac and neuronal physiology leading to fatalities upon starvation and stress (<ext-link ext-link-type="uri" xlink:href="https://tango2research.org">https://tango2research.org</ext-link>; <xref ref-type="bibr" rid="bib21">Lalani et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Miyake et al., 2022</xref>)⁠. Here, we describe the physiological role of TANGO2 and its link to starvation-induced pathologies in patients.</p><sec id="s3-1"><title>TANGO2 functions in lipid homeostasis</title><p>TANGO2 has been shown to function at the mitochondria and in the ER-to-Golgi step of the protein secretion pathway (<xref ref-type="bibr" rid="bib25">Milev et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Bard et al., 2006</xref>). Our new data reveal that TANGO2 localizes predominantly to mitochondria, but also at sites on mitochondria that are juxtaposed to LDs, and ER (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>Loss of TANGO2 in HepG2 cells has revealed four clear features: (1) a change in the abundance of several phospholipids, mainly in the ratio of LPA to PA. LPA levels are elevated, and PA is reduced; (2) reduction in CL content; (3) increase in ROS and unsaturated lipid peroxidation levels; (4) increase in LD size. The significance of these changes to TANGO2 function in physiology and pathology follows.</p><list list-type="order"><list-item><p>LPA is acylated to generate PA by lipid-modifying enzymes. The fact that LPA increases and PA decreases suggests that acylation of LPA is defective in TANGO2-lacking cells. The enzymes (LPAATs) involved in these acylation reactions are transmembrane proteins and acyl-CoA produced in the cytosol has to be imported into the lumen by membrane-embedded transporters (<xref ref-type="bibr" rid="bib13">Gonzalez-Baro and Coleman, 2017</xref>; <xref ref-type="bibr" rid="bib23">Lu and Claypool, 2015</xref>). TANGO2 lacks a transmembrane domain and cannot therefore function as an enzyme to catalyze these reactions in the lumen or the membrane of the ER or mitochondria. We suggest TANGO2 likely functions on the cytoplasmic face of mitochondria and the ER in the synthesis of acyl-CoA, or a carrier protein for acyl-CoA collection, or its metabolism. Our data show that although predominantly located to mitochondria, there is an enrichment of TANGO2 at sites juxtaposed to ER. This could be the site of LPA to PA conversion (<xref ref-type="bibr" rid="bib13">Gonzalez-Baro and Coleman, 2017</xref>; <xref ref-type="bibr" rid="bib23">Lu and Claypool, 2015</xref>). We suggest that without TANGO2, acyl-CoA is unavailable for the synthesis of PA from LPA. As a result, LPA levels rise with a concomitant drop in PA. This effect is exacerbated in nutrient-starved TANGO2-depleted cells. We noticed an increase in the expression of GPAT and AGPAT in cells depleted of TANGO2. This suggests that cells sense a reduction in the levels of PA and upregulated these enzymes that convert G3P to LPA and LPA to PA. Why do not we see restoration of PA levels in TANGO2-depleted cells. There are two possibilities: (1) TANGO2 is necessary to collect acyl-CoA at the membrane and in its absence the cells do not have the pool of acyl-CoA available for producing PA. (2) In cells lacking TANGO2, there is an increase in ROS production, which modifies unsaturated fatty acids, which cannot be incorporated into PA. These possibilities remain untested.</p></list-item><list-item><p>A reduction in CL at the inner mitochondria membrane (<xref ref-type="bibr" rid="bib10">Falabella et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Paradies et al., 2019</xref>) is likely due to reduced LPA acylation because PA is a precursor to CL. Reduced CL in TANGO2-depleted cells could explain the consequent effects on mitochondria morphology and physiology (<xref ref-type="bibr" rid="bib15">Heiman et al., 2022</xref>). In starving TANGO2-depleted cells, CL levels recover slightly compared to TANGO2-depleted cells. We suggest that when PA is low, cells likely use PG to produce CL (<xref ref-type="bibr" rid="bib10">Falabella et al., 2021</xref>). This explains reduction in PG levels in starving TANGO2-depleted cells compared. Changes in CL are associated with a number of cardiac diseases (<xref ref-type="bibr" rid="bib7">Dudek, 2017</xref>; <xref ref-type="bibr" rid="bib28">Mulligan et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Petrosillo et al., 2005</xref>)⁠. For example, Barth syndrome (BTHS) is an inherited cardiomyopathy, associated with skeletal myopathy and growth retardation (<xref ref-type="bibr" rid="bib3">Barth et al., 1996</xref>) ⁠, caused by a mutation in a mitochondria phospholipid-lysophospholipidtransacylase, involved in the biogenesis of CL (<xref ref-type="bibr" rid="bib8">Dudek and Maack, 2017</xref>). These features are similar to the pathologies associated with TANGO2 mutations in humans.</p></list-item><list-item><p>Raising ROS levels cause mitochondria dysfunction (<xref ref-type="bibr" rid="bib5">Bhatti et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Sies and Jones, 2020</xref>). These oxidative modifications could alter the lipolytic mechanisms necessary to meet ATP demands during fasting. Moreover, high ROS levels cause peroxidation of unsaturated lipids that could be required in the LPA to PA step. Also, lipid peroxidation affects intracellular membranes, which could explain the effect of protein targeting and secretion (<xref ref-type="bibr" rid="bib36">Sies and Jones, 2020</xref>).</p></list-item><list-item><p>Changes in LD volume are probably a reflection of increased incorporation to peroxidized lipids and a defect in catabolism. Several recent publications suggest that LD expansion upon oxidative stress is an evolutionarily conserved phenomenon to meliorated ROS-mediated lipid damage (<xref ref-type="bibr" rid="bib12">Gasparian et al., 2022</xref>; <xref ref-type="bibr" rid="bib16">Herms et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Liu et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Rambold et al., 2015</xref>). As a result, there is a defect in the availability of lipids for ATP production, mitochondria homeostasis, and cell signaling.</p></list-item></list><p>Altogether, TANGO2-depleted cells exhibit a change in lipid metabolism, which is aggravated in starving cells.</p></sec><sec id="s3-2"><title>TANGO2 as a haem transfer protein</title><p>A paper published recently by Chen et al. showed that loss of human TANGO2 and its orthologs in yeast and worms caused accumulation of haem in compartments like the mitochondria and lysosome-related organelles (LROs) (<xref ref-type="bibr" rid="bib37">Sun et al., 2022</xref>). The authors showed that recombinant TANGO2 has low affinity binding to ferrous and ferric haem and adding recombinant TANGO2 to mitochondria enriched membrane fractions in vitro stimulated haem transfer to apo-myoglobin. They have concluded that haem is exported from the lumen into the cytoplasm by transmembrane transporters where it is captured by TANGO2 and subsequently transferred to specific clients. Surprisingly, this was observed even in trypsinized mitochondria and the authors concluded that cytoplasmic facing domains of transmembrane proteins or attached proteins are not required in TANGO2-mediated haem transfer. Why do TANGO2-depleted cells accumulate haem in mitochondria (or LROs)? If TANGO2 captures haem post its export from mitochondria, as is reported even in trypsinized mitochondria, then haem should be distributed into the cytoplasm and not retained in mitochondria or LROs. The data also do not explain the aggravated effects of TANGO2 depletion linked to human pathologies, including a lack of any obvious sign of anaemia as would be evident for defects in haem physiology. A plausible explanation for the data is that amphipathic haem is retained in mitochondria because of altered membrane lipid composition upon TANGO2 depletion. Further work is therefore required to clarify whether the proposed function of TANGO2 in haem transfer from mitochondria is an indirect consequence of dysfunctional mitochondria lipid composition.</p></sec><sec id="s3-3"><title>Conclusion</title><p>We propose that TANGO2 has a function in events leading to specific phospholipid production. Our data show a significant change in the ratio of LPA to PA in TANGO2-depleted cells. A defect in PA levels impacts the synthesis of mitochondria CL, and to balance this deficiency, the cells use other potential substrates, such as the PG, to produce CL. The net effect is an imbalance in lipid composition or homeostasis that, we suggest, also increases ROS levels and promotes lipid peroxidation. The acyl-CoA pathway is also used for the synthesis of numerous fatty acids, and a defect in its production would change the form and function of LDs to influence cellular lipid homeostasis. Sacher et al. have reconstituted many features of TANGO2 mutations in flies (<xref ref-type="bibr" rid="bib1">Asadi et al., 2022</xref>)⁠. Interestingly, most of the aberrations in fly physiology are corrected, and an ER-to-Golgi transport defect in human cells by vitamin B5 supplement, which is used for the synthesis of CoA. In other words, loss of TANGO2 function is restored by replenishing or overdosing events leading to lipid neogenesis. CoA is used for acyl-CoA production, which is then used to acylate LPA to form PA. It has recently been shown that B-complex and multivitamins might prevent metabolic crises (<xref ref-type="bibr" rid="bib1">Asadi et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Miyake et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">Sandkuhler et al., 2023</xref>). However, why do multivitamins ameliorate metabolic crises in TANGO2 patients? Based on our results, we suggest that it is likely a combined effect of multivitamins on their antioxidant properties and in stimulating new lipids biosynthesis. The starving cells rely heavily on lipids for ATP production, and TANGO2 depleted are therefore further stressed. Our findings thus reveal the physiological role of TANGO2 and provide a handle to understand how its functional loss triggers a variety of cardiac, muscular, and neurological pathologies leading to fatalities upon conditions of starvation and stress.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture</title><p>HepG2 cells (ATCC, Cat# HB-8065) were cultured in DMEM (Lonza, Cat# SH30243.01) cell culture media supplemented with 10% (vol/vol) heat-inactivated FBS (Gibco, Cat# 10270-106) (DMEM complete), 100 units/ml penicillin, and 100 μg/ml streptomycin (Gibco), at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub>. Primary dermal fibroblasts were isolated from healthy donors (WT) and TDD patients (exon 3–9 deletion mutation in TANGO2 gene; TAN043). Human skin fibroblasts were obtained with the patient’s consent using the BCM IRB Protocol H-43240 (Clinical Trials Identifier: NCT05374616, Baylor College of Medicine, Houston, TX, USA). Fibroblasts were cultured in DMEM medium supplemented with 20% (vol/vol) heat-inactivated FBS (FBS; Gibco, Cat# 10270-106), 100 units/ml penicillin, and 100 μg/ml streptomycin (Gibco) at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub>. The cells used in our experiments were negative for the mycoplasma test. For starvation conditions, cells were incubated in OptiMEM (Gibco, Cat# 11058021) without FBS for 4 hr.</p></sec><sec id="s4-2"><title>Plasmids, RNA interference, and cell transfection</title><p>For transient protein overexpression, cells were plated and 24 hr later transfected with 1:1 ratio (DNA plasmid:Lipofectamine) using Lipofectamine 3000 reagent (Thermo Fisher Scientific) following the manufacturer’s recommendations. Plasmids generated in our laboratory: TANGO2.Isoform1-EGFP, TANGO2.Isoform1-mScarlet, Peroxisome-SKL-mTurquoise2, and GPAT4-Hairpin-mScarlet. Plasmids used and available from Addgene: ER-pmTurquoise2 (Addgene, Cat# 36204) and Mitochondria-pmTurquoise2 (Addgene, Cat# 36208). For TANGO2 silencing, cells were plated and transfected with 1:3 ratio (RNA:Lipofectamine) using Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific) following the manufacturer’s recommendations. Twenty-four hours after the first transfection, cells were transfected with a second and identical mix (ratio 1:3) of RNA:Lipofectamine. Two days after the second transfection, experiments described in this paper with siTANGO2 conditions were performed. TANGO2 RNAi sequences: Hs.Ri.TANGO2.13.1-SEQ1 (IDT technologies, Mfg ID# M498082302) and Hs.Ri.TANGO2.13.1-SEQ2 (IDT technologies, Mfg ID# M498082303).</p></sec><sec id="s4-3"><title>Antibodies and reagents</title><p>Primary antibodies used: anti-ADRP (Santa Cruz, Cat# sc-377429), anti-GFP (Roche, Cat# 11814460001), anti-β-actin (Sigma, Cat# A1978), anti-β-tubulin (Sigma, Cat# T4026), and anti-Tom20 (Santa Cruz, Cat# sc-17764). Secondary antibodies used: Alexa Fluor 594 donkey anti-rabbit (Invitrogen, Cat# A21207), Alexa Fluor 594 donkey anti-mouse (Invitrogen, Cat# A21203), Alexa Fluor 633 donkey anti-mouse (Invitrogen, Cat# A21050), Alexa Fluor 647 donkey anti-rabbit (Invitrogen, Cat# A31573), Alexa Fluor 647 donkey anti-mouse (Invitrogen, Cat# A31571), Alexa Fluor 680 donkey anti-rabbit (Invitrogen, Cat# A10043), and Alexa Fluor 800 donkey anti-mouse (Invitrogen, Cat# A32789). Reagents used were: DAPI (Invitrogen, Cat# B223), Hoechst-33342 (Sigma, Cat# B2261), HCS LipidTOX Deep Red (Thermo Fisher Scientific, Cat# H34477), Mitotracker Green (Thermo Fisher Scientific, Cat# M7514), CellROX Deep Red (Thermo Fisher Scientific, Cat# C10422), Image-iT Lipid Peroxidation Kit (Thermo Fisher Scientific, Cat# C10445), CellTrace Calcein Green, AM (Thermo Fisher Scientific, Cat# C34852), FluorSave reagent (Millipore, Cat# 345789-20), Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific, Cat# 13778075), and Lipofectamine 3000 reagent (ThermoFisher Scientific, Cat# L3000015).</p></sec><sec id="s4-4"><title>Immunoblotting</title><p>Immunoblot analysis was performed following the Biorad general protocol recommendations. Briefly, equal amounts of protein were resolved by SDS–PAGE, transferred onto 0.45-µm polyvinylidene difluoride (PVDF) membranes (Amersham), and incubated overnight with anti-GFP (1:1000; Abcam), anti-β-actin (1:10,000; Sigma) antibodies followed by Alexa-conjugated secondary antibodies (1:20,000; Invitrogen) for 1 hr at 37°C. Bands were visualized an Odyssey CLX (LI-COR Biosciences).</p></sec><sec id="s4-5"><title>Immunofluorescence and immunohistochemistry</title><p>HepG2 cells (1 × 10<sup>5</sup> cells per well) were grown on coverslips. After mock or siTANGO2 silencing, cells were fixed with 3% paraformaldehyde, quenched, and incubated overnight with anti-ADRP (1:1000) at 4°C followed by Alexa Fluor 647 donkey anti-mouse (1:2000) and DAPI (1:10,000) for 1 hr at 37°C. Coverslips were washed and mounted in FluorSave reagent. Samples were analyzed and high-resolution images were acquired in an inverted Leica TCS SP8 confocal microscope equipped with photomultipliers and hybrid detectors. Images were processed using ImageJ software.</p></sec><sec id="s4-6"><title>Förster resonance energy transfer measurement</title><p>For the energy donor and acceptor pair we selected NeonGreen and mScarlet, respectively, as they have been previously described as a suitable Förster resonance energy transfer (FRET) pair (<xref ref-type="bibr" rid="bib24">McCullock et al., 2020</xref>). To measure the energy transfer between the two we used the ‘acceptor photobleaching’ method for its simplicity and robustness as has been previously described (<xref ref-type="bibr" rid="bib14">Grecco and Bastiaens, 2013</xref>). By comparing the change in intensity of the quenched (pre-photobleaching) and unquenched (post-photobleaching) images of the donor we can measure FRET between TANGO2mScarlet and Tom20-Alexa 633 using the following formula: FRET efficiency = 1 − (quenched donor/unquenched donor). To calculate the FRET efficiency we used averaged intensity values of each image. To calculate FRET maps we used pixel by pixel calculation of the FRET efficiency. All image calculations were processed using ImageJ software.</p></sec><sec id="s4-7"><title>Live-cell imaging</title><p>HepG2 cells (2.5 × 10<sup>5</sup> cells per dish) were grown on 35-mm polymer-bottom dishes (ibidi). After mock or siTANGO2 silencing, cells were washed and the cell medium was replaced with the appropriate conditioned medium for the indicated period of time. The cells were then washed several times to remove the conditioned medium and incubated with the appropriate reagent (Hoechst-33342, HCS LipiTOX Deep Red, MitoTracker Green). Finally, after several washes, cells were used to perform the experiments described in the paper. Samples were analyzed at 37°C in 5% CO<sub>2</sub> atmosphere. High-resolution and time-lapse images were acquired in an inverted Leica STELLARIS confocal microscope equipped with photomultipliers and hybrid detectors. Images were processed using ImageJ software. For co-localization analysis, we calculated the Pearson correlation coefficient (<italic>r</italic>) of confocal images with the coloc2 plugin in ImageJ software. To quantify the volume of LDs in confocal images, we developed a macro to identify each voxel (pixel<sup>3</sup>) stained by the lipophilic marker LipidTOX in <italic>z</italic>-stacks. We then selected five <italic>z</italic>-stacks from each condition. This macro automatically identified and distinguished the positive from the negative particles on each slide and generated a data set with the volume of each particle, the number of particles, and the total volume of positive particles. This method reduced the chances in counting errors or biases.</p></sec><sec id="s4-8"><title>Flow cytometry assays</title><p>To examine the total LDs volume, HepG2 cells (2 × 10<sup>5</sup> cells per well) were seeded in 24-well plates (Thermo Fisher Scientific). Two days after the second silencing (Mock or siTANGO2), cells were washed and the cell medium was changed with the appropriate medium for the times indicated. The cells were then washed several times to remove the conditioned medium and incubated with the appropriate reagent (CellROX Deep Red, Lipid Peroxidation Red/Green, HCS LipidTOX Deep Red, MitoTracker Green, Calcein AM, DAPI). Cells were gently detached using trypsin and washed several times before flow cytometry analyses. Flow cytometry assays were performed by technical triplicates of at least 10,000 cells per condition each time in three independent experiments. In the statistical model, these triplicates are nested together. Flow cytometry analysis was performed using a BD LSR II Flow Cytometer (Becton Dickinson Biosciences).</p></sec><sec id="s4-9"><title>Lipid extraction for mass spectrometry lipidomics</title><p>Mass spectrometry-based lipid analysis was performed by Lipotype GmbH (Dresden, Germany) as described (<xref ref-type="bibr" rid="bib39">Surma et al., 2021</xref>)⁠. Lipids were extracted using a chloroform/methanol procedure (<xref ref-type="bibr" rid="bib9">Ejsing et al., 2009</xref>)⁠. Samples were spiked with internal lipid standard mixture containing: cardiolipin 14:0/14:0/14:0/14:0 (CL), ceramide 18:1;2/17:0 (Cer), diacylglycerol 17:0/17:0 (DAG), hexosylceramide 18:1;2/12:0 (HexCer), lyso-phosphatidate 17:0 (LPA), lyso-phosphatidylcholine 12:0 (LPC), lyso-phosphatidylethanolamine 17:1 (LPE), lyso-phosphatidylglycerol 17:1 (LPG), lyso-phosphatidylinositol 17:1 (LPI), lyso-phosphatidylserine 17:1 (LPS), phosphatidate 17:0/17:0 (PA), phosphatidylcholine 17:0/17:0 (PC), phosphatidylethanolamine 17:0/17:0 (PE), phosphatidylglycerol 17:0/17:0 (PG), phosphatidylinositol 16:0/16:0 (PI), phosphatidylserine 17:0/17:0 (PS), cholesterol ester 20:0 (CE), sphingomyelin 18:1;2/12:0;0 (SM), and triacylglycerol 17:0/17:0/17:0 (TAG). After extraction, the organic phase was transferred to an infusion plate and dried in a speed vacuum concentrator. The dry extract was re-suspended in 7.5 mM ammonium formiate in chloroform/methanol/propanol (1:2:4, vol:vol:vol). All liquid handling steps were performed using Hamilton Robotics STARlet robotic platform with the Anti Droplet Control feature for organic solvents pipetting.</p></sec><sec id="s4-10"><title>MS data acquisition</title><p>Samples were analyzed by direct infusion on a QExactive mass spectrometer (Thermo Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences). Samples were analyzed in both positive and negative ion modes with a resolution of Rm/z = 200 = 280,000 for MS and Rm/z = 200 = 17,500 for tandem mass spectrometry (MSMS) experiments, in a single acquisition. MSMS was triggered by an inclusion list encompassing corresponding MS mass ranges scanned in 1 Da increments (<xref ref-type="bibr" rid="bib38">Surma et al., 2015</xref>)⁠. Both MS and MSMS data were combined to monitor CE, DAG, and TAG ions as ammonium adducts; LPC, LPC O-, PC, and PC O-, as formiate adducts; and CL, LPS, PA, PE, PE O-, PG, PI, and PS as deprotonated anions. MS only was used to monitor LPA, LPE, LPE O-, LPG, and LPI as deprotonated anions; Cer, HexCer, and SM as formiate adducts.</p></sec><sec id="s4-11"><title>Lipidomics data analysis and post-processing</title><p>Data were analyzed with an in-house developed lipid identification software based on LipidXplorer (<xref ref-type="bibr" rid="bib17">Herzog et al., 2012</xref>). Data post-processing and normalization were performed using an in-house developed data management system. Only lipid identifications with a signal-to-noise ratio &gt;5, and a signal intensity fivefold higher than in corresponding blank samples were considered for further data analysis.</p></sec><sec id="s4-12"><title>RNA extraction and RT-qPCR</title><p>RNA was extracted using an RNeasy mini kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions for direct cell lysis in a 12-well plate. Luna Universal One-Step RT-qPCR Kit (New England Biolabs, Ipswich, MA) was used for RT-qPCR reactions. Briefly, 10 μl reaction contained: 5 μl Reaction MasterMix, 0.5 μl EnzymeMix, 0.8 μl primers (10 μM, Fwd + Rv mixed), 1 μl of RNA (20 ng), and 2.7 μl water. RT-qPCR reactions were performed in duplicate or triplicate, and three biological repeats were analyzed for each condition. RT-qPCRs were performed in a LightCycler 480 System (Roche, Basel, Switzerland) with conditions as follows: 55°C for 10 min, 95°C for 1 min, followed by 45 cycles of 95°C for 10 s, 60°C for 30 s. The cycle threshold value (Ct) was calculated for each sample and normalized to GAPDH. The relative expression levels were calculated using ΔΔCT method. Primer sequences are included in the following table:</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Gene</th><th align="left" valign="top">Forward primer (5′–3′)</th><th align="left" valign="top">Reverse primer (5′–3′)</th></tr></thead><tbody><tr><td align="left" valign="top"><bold>AGPAT1</bold></td><td align="left" valign="top">GGTACTCGCAACGACAATGG</td><td align="left" valign="top">TTGGTGTTGTAGAAGGAGGAGAAG</td></tr><tr><td align="left" valign="top"><bold>AGPAT2</bold></td><td align="left" valign="top">AACGTGGCGCCTTCCA</td><td align="left" valign="top">GAAGTCTTGGTAGGAGGACATGACT</td></tr><tr><td align="left" valign="top"><bold>AGPAT3</bold></td><td align="left" valign="top">CTCCAAGGTCCTCGCTAAGAAG</td><td align="left" valign="top">CCGCTTGCAGAACACAATCTC</td></tr><tr><td align="left" valign="top"><bold>AGPAT4</bold></td><td align="left" valign="top">CACGGAATGCACCATCTTCA</td><td align="left" valign="top">GAACCACGATGGCATTTTCCT</td></tr><tr><td align="left" valign="top"><bold>AGPAT5</bold></td><td align="left" valign="top">CTGGTGCTCCACACGTACTC</td><td align="left" valign="top">CCAGGCCAACACGTAGGTG</td></tr><tr><td align="left" valign="top"><bold>GPAT1</bold></td><td align="left" valign="top">AACCCCAGTATCCCGTCTTT</td><td align="left" valign="top">CAGTCACATTGGTGGCAAAC</td></tr><tr><td align="left" valign="top"><bold>GPAT2</bold></td><td align="left" valign="top">GGCTGACGGAGGAGATACTG</td><td align="left" valign="top">AGTTGTGCCAGGTGTGTGAG</td></tr><tr><td align="left" valign="top"><bold>GPAT3</bold></td><td align="left" valign="top">ACAGCAGCCTCAAAAACTGG</td><td align="left" valign="top">CAATGGGGGAAGTATGGTTG</td></tr><tr><td align="left" valign="top"><bold>GPAT4</bold></td><td align="left" valign="top">TGCCAAATGGGAGGTTTAAG</td><td align="left" valign="top">GCCACCATTTCTTGGTCTGT</td></tr><tr><td align="left" valign="top"><bold>LPIN1</bold></td><td align="left" valign="top">CAGTCGAGGCTCAGACCA</td><td align="left" valign="top">TTCCCCGTTGATTTCTATGTCA</td></tr><tr><td align="left" valign="top"><bold>LPIN2</bold></td><td align="left" valign="top">CCTCTCCTCAGACCAGATCG</td><td align="left" valign="top">GGAGAATCTGTCCCAAAGCA</td></tr><tr><td align="left" valign="top"><bold>LPIN3</bold></td><td align="left" valign="top">AGAAGTCTTCACTGCAGCCC</td><td align="left" valign="top">CAGCTCCGAGTCGCTCTTAG</td></tr><tr><td align="left" valign="top"><bold>LPIN4</bold></td><td align="left" valign="top">CCTTCAGCCTGACACAGAGG</td><td align="left" valign="top">AAGCGCTGCATTCTCAGAGT</td></tr><tr><td align="left" valign="top"><bold>PLA2G4A</bold></td><td align="left" valign="top">TCTACAACCCCTGACAGCAG</td><td align="left" valign="top">GCTGTCCCTAGAGTTTCATCCA</td></tr><tr><td align="left" valign="top"><bold>TANGO2</bold></td><td align="left" valign="top">CCGACCCTCCAAGTTAGCTG</td><td align="left" valign="top">TAGTTGGTGAGTGCTGCCAG</td></tr><tr><td align="left" valign="top"><bold>TANGO2</bold></td><td align="left" valign="top">CACAGCAAAGGGAGACGTCA</td><td align="left" valign="top">GTTCCACAGCCTCCAGGAAG</td></tr></tbody></table></table-wrap></sec><sec id="s4-13"><title>Bioinformatic analysis</title><p>The repository used in the in silico analysis of TANGO2 orthologs and isoforms is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/alessiovignoli/TANGO2">https://github.com/alessiovignoli/TANGO2</ext-link> (copy archived at <xref ref-type="bibr" rid="bib41">Vignoli, 2023</xref>).</p><p>The code used in the development of the macro to identify each voxel (voxel = pixel<sup>3</sup> = pixel × pixel × pixel) is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/AAMateo/Lipid_Droplets">https://github.com/AAMateo/Lipid_Droplets</ext-link> (copy archived at <xref ref-type="bibr" rid="bib11">Farre, 2023</xref>).</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad) and R software. Data represent the mean ± standard deviations of <italic>N</italic> experiments. For simple unpaired analysis between two groups, Student’s <italic>t</italic>-test with subsequent Welch’s correction was choosen. For multiple comparisons, analysis of variance with subsequent Bonferroni’s or Tukey’s post-tests was used. p values less than 0.05 were considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Software, Methodology</p></fn><fn fn-type="con" id="con6"><p>Software, Methodology</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85345-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>'TANGO2–Source data files' have been submitted to Dryad (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.rn8pk0pg5">https://doi.org/10.5061/dryad.rn8pk0pg5</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Lujan</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>TANGO2–Source data files</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.rn8pk0pg5</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all members of the Malhotra laboratory for valuable discussions and critical reading of the manuscript. We thank Aida Rodriguez for advice with ROS analysis; Albert Pol and Albert Herms for advice with lipid metabolic experiments; the staff of the CRG/UPF Flow Cytometry Unit for advice with flow cytometry analysis and the staff of the CRG Advanced Light Microscopy Unit for invaluable technical help. We acknowledge the support of the Spanish Ministry of Science, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. V Malhotra is an Institució Catalana de Recerca i Estudis Avançats professor at the Centre for Genomic Regulation. V Malhotra is an Institució Catalana de Recerca i Estudis Avançats professor at the Centre for Genomic Regulation Work in the Malhotra lab is funded by grants from the Spanish Ministry of Economy and Competitiveness (Plan Nacional to VM: PID2019-105518GB-I00) and the European Research Council Synergy Grant (ERC-2020-SyG-Proposal No. 951146). AL is funded by the European Molecular Biology Organization (EMBO ALTF 659-2021), JW is funded by the European Research Council (H2020-MSCA-IF-2019-894115). OF is funded by the Ramon y Cajal program (RYC-2016-20919). This work reflects only the authors’ views, and the EU Community is not liable for any use that may be made of the information contained therein.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Asadi</surname><given-names>P</given-names></name><name><surname>Milev</surname><given-names>MP</given-names></name><name><surname>Saint-Dic</surname><given-names>D</given-names></name><name><surname>Gamberi</surname><given-names>C</given-names></name><name><surname>Sacher</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Vitamin B5, A Coenzyme A Precursor, Rescues TANGO2 Deficiency Disease-Associated Defects in <italic>Drosophila</italic> and Human Cells</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.11.04.514597</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Casano</surname><given-names>L</given-names></name><name><surname>Mallabiabarrena</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>E</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Kitayama</surname><given-names>H</given-names></name><name><surname>Guizzunti</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wendler</surname><given-names>F</given-names></name><name><surname>Dasgupta</surname><given-names>R</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name><name><surname>Malhotra</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Functional genomics reveals genes involved in protein secretion and golgi organization</article-title><source>Nature</source><volume>439</volume><fpage>604</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature04377</pub-id><pub-id pub-id-type="pmid">16452979</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>PG</given-names></name><name><surname>Van den Bogert</surname><given-names>C</given-names></name><name><surname>Bolhuis</surname><given-names>PA</given-names></name><name><surname>Scholte</surname><given-names>HR</given-names></name><name><surname>van Gennip</surname><given-names>AH</given-names></name><name><surname>Schutgens</surname><given-names>RB</given-names></name><name><surname>Ketel</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>X-linked cardioskeletal myopathy and neutropenia (barth syndrome): respiratory-chain abnormalities in cultured fibroblasts</article-title><source>Journal of Inherited Metabolic Disease</source><volume>19</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/BF01799418</pub-id><pub-id pub-id-type="pmid">8739954</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bérat</surname><given-names>CM</given-names></name><name><surname>Montealegre</surname><given-names>S</given-names></name><name><surname>Wiedemann</surname><given-names>A</given-names></name><name><surname>Nuzum</surname><given-names>MLC</given-names></name><name><surname>Blondel</surname><given-names>A</given-names></name><name><surname>Debruge</surname><given-names>H</given-names></name><name><surname>Cano</surname><given-names>A</given-names></name><name><surname>Chabrol</surname><given-names>B</given-names></name><name><surname>Hoebeke</surname><given-names>C</given-names></name><name><surname>Polak</surname><given-names>M</given-names></name><name><surname>Stoupa</surname><given-names>A</given-names></name><name><surname>Feillet</surname><given-names>F</given-names></name><name><surname>Torre</surname><given-names>S</given-names></name><name><surname>Boddaert</surname><given-names>N</given-names></name><name><surname>Bruel</surname><given-names>H</given-names></name><name><surname>Barth</surname><given-names>M</given-names></name><name><surname>Damaj</surname><given-names>L</given-names></name><name><surname>Abi-Wardé</surname><given-names>MT</given-names></name><name><surname>Afenjar</surname><given-names>A</given-names></name><name><surname>Benoist</surname><given-names>JF</given-names></name><name><surname>Madrange</surname><given-names>M</given-names></name><name><surname>Caccavelli</surname><given-names>L</given-names></name><name><surname>Renard</surname><given-names>P</given-names></name><name><surname>Hubas</surname><given-names>A</given-names></name><name><surname>Nusbaum</surname><given-names>P</given-names></name><name><surname>Pontoizeau</surname><given-names>C</given-names></name><name><surname>Gobin</surname><given-names>S</given-names></name><name><surname>van Endert</surname><given-names>P</given-names></name><name><surname>Ottolenghi</surname><given-names>C</given-names></name><name><surname>Maltret</surname><given-names>A</given-names></name><name><surname>de Lonlay</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clinical and biological characterization of 20 patients with TANGO2 deficiency indicates novel triggers of metabolic crises and NO primary energetic defect</article-title><source>Journal of Inherited Metabolic Disease</source><volume>44</volume><fpage>415</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1002/jimd.12314</pub-id><pub-id pub-id-type="pmid">32929747</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatti</surname><given-names>JS</given-names></name><name><surname>Bhatti</surname><given-names>GK</given-names></name><name><surname>Reddy</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies</article-title><source>Biochimica et Biophysica Acta. Molecular Basis of Disease</source><volume>1863</volume><fpage>1066</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2016.11.010</pub-id><pub-id pub-id-type="pmid">27836629</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broussard</surname><given-names>JA</given-names></name><name><surname>Rappaz</surname><given-names>B</given-names></name><name><surname>Webb</surname><given-names>DJ</given-names></name><name><surname>Brown</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fluorescence resonance energy transfer microscopy as demonstrated by measuring the activation of the serine/threonine kinase akt</article-title><source>Nature Protocols</source><volume>8</volume><fpage>265</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.147</pub-id><pub-id pub-id-type="pmid">23306460</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Role of cardiolipin in mitochondrial signaling pathways</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>5</volume><elocation-id>90</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2017.00090</pub-id><pub-id pub-id-type="pmid">29034233</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudek</surname><given-names>J</given-names></name><name><surname>Maack</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Barth syndrome cardiomyopathy</article-title><source>Cardiovascular Research</source><volume>113</volume><fpage>399</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx014</pub-id><pub-id pub-id-type="pmid">28158532</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ejsing</surname><given-names>CS</given-names></name><name><surname>Sampaio</surname><given-names>JL</given-names></name><name><surname>Surendranath</surname><given-names>V</given-names></name><name><surname>Duchoslav</surname><given-names>E</given-names></name><name><surname>Ekroos</surname><given-names>K</given-names></name><name><surname>Klemm</surname><given-names>RW</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Shevchenko</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry</article-title><source>PNAS</source><volume>106</volume><fpage>2136</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811700106</pub-id><pub-id pub-id-type="pmid">19174513</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falabella</surname><given-names>M</given-names></name><name><surname>Vernon</surname><given-names>HJ</given-names></name><name><surname>Hanna</surname><given-names>MG</given-names></name><name><surname>Claypool</surname><given-names>SM</given-names></name><name><surname>Pitceathly</surname><given-names>RDS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cardiolipin, mitochondria, and neurological disease</article-title><source>Trends in Endocrinology and Metabolism</source><volume>32</volume><fpage>224</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2021.01.006</pub-id><pub-id pub-id-type="pmid">33640250</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Farre</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Lipid_droplets</data-title><version designator="swh:1:rev:6fee4d15fc064dae7e70be11d6fc4772ecf2aac6">swh:1:rev:6fee4d15fc064dae7e70be11d6fc4772ecf2aac6</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:48b058a601f2477e88d88660c7fd4d45f8685cdc;origin=https://github.com/AAMateo/Lipid_Droplets;visit=swh:1:snp:c4add86570f4c773769068fef2dd701be7eda60e;anchor=swh:1:rev:6fee4d15fc064dae7e70be11d6fc4772ecf2aac6">https://archive.softwareheritage.org/swh:1:dir:48b058a601f2477e88d88660c7fd4d45f8685cdc;origin=https://github.com/AAMateo/Lipid_Droplets;visit=swh:1:snp:c4add86570f4c773769068fef2dd701be7eda60e;anchor=swh:1:rev:6fee4d15fc064dae7e70be11d6fc4772ecf2aac6</ext-link></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparian</surname><given-names>A</given-names></name><name><surname>Aksenova</surname><given-names>M</given-names></name><name><surname>Oliver</surname><given-names>D</given-names></name><name><surname>Levina</surname><given-names>E</given-names></name><name><surname>Doran</surname><given-names>R</given-names></name><name><surname>Lucius</surname><given-names>M</given-names></name><name><surname>Piroli</surname><given-names>G</given-names></name><name><surname>Oleinik</surname><given-names>N</given-names></name><name><surname>Ogretmen</surname><given-names>B</given-names></name><name><surname>Mythreye</surname><given-names>K</given-names></name><name><surname>Frizzell</surname><given-names>N</given-names></name><name><surname>Broude</surname><given-names>E</given-names></name><name><surname>Wyatt</surname><given-names>MD</given-names></name><name><surname>Shtutman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Depletion of COPI in cancer cells: the role of reactive oxygen species in the induction of lipid accumulation, noncanonical lipophagy and apoptosis</article-title><source>Molecular Biology of the Cell</source><volume>33</volume><elocation-id>ar135</elocation-id><pub-id pub-id-type="doi">10.1091/mbc.E21-08-0420</pub-id><pub-id pub-id-type="pmid">36222847</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Baro</surname><given-names>MR</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mitochondrial acyltransferases and glycerophospholipid metabolism</article-title><source>Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids</source><volume>1862</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2016.06.023</pub-id><pub-id pub-id-type="pmid">27377347</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grecco</surname><given-names>HE</given-names></name><name><surname>Bastiaens</surname><given-names>PIH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Quantifying cellular dynamics by fluorescence resonance energy transfer (FRET) microscopy</article-title><source>Current Protocols in Neuroscience</source><volume>Chapter 5</volume><elocation-id>Unit5</elocation-id><pub-id pub-id-type="doi">10.1002/0471142301.ns0522s63</pub-id><pub-id pub-id-type="pmid">23559306</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiman</surname><given-names>P</given-names></name><name><surname>Mohsen</surname><given-names>AW</given-names></name><name><surname>Karunanidhi</surname><given-names>A</given-names></name><name><surname>St Croix</surname><given-names>C</given-names></name><name><surname>Watkins</surname><given-names>S</given-names></name><name><surname>Koppes</surname><given-names>E</given-names></name><name><surname>Haas</surname><given-names>R</given-names></name><name><surname>Vockley</surname><given-names>J</given-names></name><name><surname>Ghaloul-Gonzalez</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mitochondrial dysfunction associated with TANGO2 deficiency</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>3045</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-07076-9</pub-id><pub-id pub-id-type="pmid">35197517</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herms</surname><given-names>A</given-names></name><name><surname>Bosch</surname><given-names>M</given-names></name><name><surname>Ariotti</surname><given-names>N</given-names></name><name><surname>Reddy</surname><given-names>BJN</given-names></name><name><surname>Fajardo</surname><given-names>A</given-names></name><name><surname>Fernández-Vidal</surname><given-names>A</given-names></name><name><surname>Alvarez-Guaita</surname><given-names>A</given-names></name><name><surname>Fernández-Rojo</surname><given-names>MA</given-names></name><name><surname>Rentero</surname><given-names>C</given-names></name><name><surname>Tebar</surname><given-names>F</given-names></name><name><surname>Enrich</surname><given-names>C</given-names></name><name><surname>Geli</surname><given-names>MI</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name><name><surname>Gross</surname><given-names>SP</given-names></name><name><surname>Pol</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cell-to-cell heterogeneity in lipid droplets suggests a mechanism to reduce lipotoxicity</article-title><source>Current Biology</source><volume>23</volume><fpage>1489</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2013.06.032</pub-id><pub-id pub-id-type="pmid">23871243</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herzog</surname><given-names>R</given-names></name><name><surname>Schuhmann</surname><given-names>K</given-names></name><name><surname>Schwudke</surname><given-names>D</given-names></name><name><surname>Sampaio</surname><given-names>JL</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Shevchenko</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>LipidXplorer: a software for consensual cross-platform lipidomics</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e29851</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0029851</pub-id><pub-id pub-id-type="pmid">22272252</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoebeke</surname><given-names>C</given-names></name><name><surname>Cano</surname><given-names>A</given-names></name><name><surname>De Lonlay</surname><given-names>P</given-names></name><name><surname>Chabrol</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clinical phenotype associated with TANGO2 gene mutation</article-title><source>Archives de Pediatrie</source><volume>28</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.arcped.2020.11.004</pub-id><pub-id pub-id-type="pmid">33342685</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennions</surname><given-names>E</given-names></name><name><surname>Hedberg-Oldfors</surname><given-names>C</given-names></name><name><surname>Berglund</surname><given-names>AK</given-names></name><name><surname>Kollberg</surname><given-names>G</given-names></name><name><surname>Törnhage</surname><given-names>CJ</given-names></name><name><surname>Eklund</surname><given-names>EA</given-names></name><name><surname>Oldfors</surname><given-names>A</given-names></name><name><surname>Verloo</surname><given-names>P</given-names></name><name><surname>Vanlander</surname><given-names>AV</given-names></name><name><surname>De Meirleir</surname><given-names>L</given-names></name><name><surname>Seneca</surname><given-names>S</given-names></name><name><surname>Sterky</surname><given-names>FH</given-names></name><name><surname>Darin</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TANGO2 deficiency as a cause of neurodevelopmental delay with indirect effects on mitochondrial energy metabolism</article-title><source>Journal of Inherited Metabolic Disease</source><volume>42</volume><fpage>898</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1002/jimd.12149</pub-id><pub-id pub-id-type="pmid">31276219</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremer</surname><given-names>LS</given-names></name><name><surname>Distelmaier</surname><given-names>F</given-names></name><name><surname>Alhaddad</surname><given-names>B</given-names></name><name><surname>Hempel</surname><given-names>M</given-names></name><name><surname>Iuso</surname><given-names>A</given-names></name><name><surname>Küpper</surname><given-names>C</given-names></name><name><surname>Mühlhausen</surname><given-names>C</given-names></name><name><surname>Kovacs-Nagy</surname><given-names>R</given-names></name><name><surname>Satanovskij</surname><given-names>R</given-names></name><name><surname>Graf</surname><given-names>E</given-names></name><name><surname>Berutti</surname><given-names>R</given-names></name><name><surname>Eckstein</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>Sauer</surname><given-names>S</given-names></name><name><surname>Hoffmann</surname><given-names>GF</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>Santer</surname><given-names>R</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Klopstock</surname><given-names>T</given-names></name><name><surname>Prokisch</surname><given-names>H</given-names></name><name><surname>Haack</surname><given-names>TB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bi-allelic truncating mutations in TANGO2 cause infancy-onset recurrent metabolic crises with encephalocardiomyopathy</article-title><source>American Journal of Human Genetics</source><volume>98</volume><fpage>358</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2015.12.009</pub-id><pub-id pub-id-type="pmid">26805782</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalani</surname><given-names>SR</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Watkin</surname><given-names>LB</given-names></name><name><surname>Chiang</surname><given-names>T</given-names></name><name><surname>Leduc</surname><given-names>MS</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Vetrini</surname><given-names>F</given-names></name><name><surname>Miyake</surname><given-names>CY</given-names></name><name><surname>Shinawi</surname><given-names>M</given-names></name><name><surname>Gambin</surname><given-names>T</given-names></name><name><surname>Eldomery</surname><given-names>MK</given-names></name><name><surname>Akdemir</surname><given-names>ZHC</given-names></name><name><surname>Emrick</surname><given-names>L</given-names></name><name><surname>Wilnai</surname><given-names>Y</given-names></name><name><surname>Schelley</surname><given-names>S</given-names></name><name><surname>Koenig</surname><given-names>MK</given-names></name><name><surname>Memon</surname><given-names>N</given-names></name><name><surname>Farach</surname><given-names>LS</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><name><surname>Azamian</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>P</given-names></name><name><surname>Zapata</surname><given-names>G</given-names></name><name><surname>Jhangiani</surname><given-names>SN</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Lotze</surname><given-names>T</given-names></name><name><surname>Clark</surname><given-names>G</given-names></name><name><surname>Wilfong</surname><given-names>A</given-names></name><name><surname>Northrup</surname><given-names>H</given-names></name><name><surname>Adesina</surname><given-names>A</given-names></name><name><surname>Bacino</surname><given-names>CA</given-names></name><name><surname>Scaglia</surname><given-names>F</given-names></name><name><surname>Bonnen</surname><given-names>PE</given-names></name><name><surname>Crosson</surname><given-names>J</given-names></name><name><surname>Duis</surname><given-names>J</given-names></name><name><surname>Maegawa</surname><given-names>GHB</given-names></name><name><surname>Coman</surname><given-names>D</given-names></name><name><surname>Inwood</surname><given-names>A</given-names></name><name><surname>McGill</surname><given-names>J</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Graham</surname><given-names>B</given-names></name><name><surname>Beaudet</surname><given-names>A</given-names></name><name><surname>Eng</surname><given-names>CM</given-names></name><name><surname>Hanchard</surname><given-names>NA</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Recurrent muscle weakness with rhabdomyolysis, metabolic crises, and cardiac arrhythmia due to bi-allelic TANGO2 mutations</article-title><source>American Journal of Human Genetics</source><volume>98</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2015.12.008</pub-id><pub-id pub-id-type="pmid">26805781</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Sandoval</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Jaiswal</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>BH</given-names></name><name><surname>Quintana</surname><given-names>A</given-names></name><name><surname>Bellen</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration</article-title><source>Cell</source><volume>160</volume><fpage>177</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.12.019</pub-id><pub-id pub-id-type="pmid">25594180</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YW</given-names></name><name><surname>Claypool</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Disorders of phospholipid metabolism: an emerging class of mitochondrial disease due to defects in nuclear genes</article-title><source>Frontiers in Genetics</source><volume>6</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2015.00003</pub-id><pub-id pub-id-type="pmid">25691889</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullock</surname><given-names>TW</given-names></name><name><surname>MacLean</surname><given-names>DM</given-names></name><name><surname>Kammermeier</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comparing the performance of mscarlet-I, mruby3, and mcherry as FRET acceptors for mneongreen</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0219886</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0219886</pub-id><pub-id pub-id-type="pmid">32023253</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milev</surname><given-names>MP</given-names></name><name><surname>Saint-Dic</surname><given-names>D</given-names></name><name><surname>Zardoui</surname><given-names>K</given-names></name><name><surname>Klopstock</surname><given-names>T</given-names></name><name><surname>Law</surname><given-names>C</given-names></name><name><surname>Distelmaier</surname><given-names>F</given-names></name><name><surname>Sacher</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The phenotype associated with variants in TANGO2 may be explained by a dual role of the protein in ER-to-golgi transport and at the mitochondria</article-title><source>Journal of Inherited Metabolic Disease</source><volume>44</volume><fpage>426</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1002/jimd.12312</pub-id><pub-id pub-id-type="pmid">32909282</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mingirulli</surname><given-names>N</given-names></name><name><surname>Pyle</surname><given-names>A</given-names></name><name><surname>Hathazi</surname><given-names>D</given-names></name><name><surname>Alston</surname><given-names>CL</given-names></name><name><surname>Kohlschmidt</surname><given-names>N</given-names></name><name><surname>O’Grady</surname><given-names>G</given-names></name><name><surname>Waddell</surname><given-names>L</given-names></name><name><surname>Evesson</surname><given-names>F</given-names></name><name><surname>Cooper</surname><given-names>SBT</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Duff</surname><given-names>J</given-names></name><name><surname>Topf</surname><given-names>A</given-names></name><name><surname>Yubero</surname><given-names>D</given-names></name><name><surname>Jou</surname><given-names>C</given-names></name><name><surname>Nascimento</surname><given-names>A</given-names></name><name><surname>Ortez</surname><given-names>C</given-names></name><name><surname>García-Cazorla</surname><given-names>A</given-names></name><name><surname>Gross</surname><given-names>C</given-names></name><name><surname>O’Callaghan</surname><given-names>M</given-names></name><name><surname>Santra</surname><given-names>S</given-names></name><name><surname>Preece</surname><given-names>MA</given-names></name><name><surname>Champion</surname><given-names>M</given-names></name><name><surname>Korenev</surname><given-names>S</given-names></name><name><surname>Chronopoulou</surname><given-names>E</given-names></name><name><surname>Anirban</surname><given-names>M</given-names></name><name><surname>Pierre</surname><given-names>G</given-names></name><name><surname>McArthur</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>K</given-names></name><name><surname>Navas</surname><given-names>P</given-names></name><name><surname>Ribes</surname><given-names>A</given-names></name><name><surname>Tort</surname><given-names>F</given-names></name><name><surname>Schlüter</surname><given-names>A</given-names></name><name><surname>Pujol</surname><given-names>A</given-names></name><name><surname>Montero</surname><given-names>R</given-names></name><name><surname>Sarquella</surname><given-names>G</given-names></name><name><surname>Lochmüller</surname><given-names>H</given-names></name><name><surname>Jiménez-Mallebrera</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>RW</given-names></name><name><surname>Artuch</surname><given-names>R</given-names></name><name><surname>Kirschner</surname><given-names>J</given-names></name><name><surname>Grünert</surname><given-names>SC</given-names></name><name><surname>Roos</surname><given-names>A</given-names></name><name><surname>Horvath</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical presentation and proteomic signature of patients with TANGO2 mutations</article-title><source>Journal of Inherited Metabolic Disease</source><volume>43</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1002/jimd.12156</pub-id><pub-id pub-id-type="pmid">31339582</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>CY</given-names></name><name><surname>Lay</surname><given-names>EJ</given-names></name><name><surname>Beach</surname><given-names>CM</given-names></name><name><surname>Ceresnak</surname><given-names>SR</given-names></name><name><surname>Delauz</surname><given-names>CM</given-names></name><name><surname>Howard</surname><given-names>TS</given-names></name><name><surname>Janson</surname><given-names>CM</given-names></name><name><surname>Jardine</surname><given-names>K</given-names></name><name><surname>Kannankeril</surname><given-names>PJ</given-names></name><name><surname>Kava</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Liberman</surname><given-names>L</given-names></name><name><surname>Macicek</surname><given-names>SL</given-names></name><name><surname>Pham</surname><given-names>TD</given-names></name><name><surname>Robertson</surname><given-names>T</given-names></name><name><surname>Valdes</surname><given-names>SO</given-names></name><name><surname>Webster</surname><given-names>G</given-names></name><name><surname>Stephens</surname><given-names>SB</given-names></name><name><surname>Milewicz</surname><given-names>DM</given-names></name><name><surname>Azamian</surname><given-names>M</given-names></name><name><surname>Ehsan</surname><given-names>SA</given-names></name><name><surname>Houck</surname><given-names>KM</given-names></name><name><surname>Soler-Alfonso</surname><given-names>C</given-names></name><name><surname>Glinton</surname><given-names>KE</given-names></name><name><surname>Tosur</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Lalani</surname><given-names>SR</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cardiac crises: cardiac arrhythmias and cardiomyopathy during TANGO2 deficiency related metabolic crises</article-title><source>Heart Rhythm</source><volume>19</volume><fpage>1673</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2022.05.009</pub-id><pub-id pub-id-type="pmid">35568137</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>CM</given-names></name><name><surname>Le</surname><given-names>CH</given-names></name><name><surname>deMooy</surname><given-names>AB</given-names></name><name><surname>Nelson</surname><given-names>CB</given-names></name><name><surname>Chicco</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibition of delta-6 desaturase reverses cardiolipin remodeling and prevents contractile dysfunction in the aged mouse heart without altering mitochondrial respiratory function</article-title><source>The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</source><volume>69</volume><fpage>799</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1093/gerona/glt209</pub-id><pub-id pub-id-type="pmid">24418793</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paradies</surname><given-names>G</given-names></name><name><surname>Paradies</surname><given-names>V</given-names></name><name><surname>Ruggiero</surname><given-names>FM</given-names></name><name><surname>Petrosillo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Role of cardiolipin in mitochondrial function and dynamics in health and disease: molecular and pharmacological aspects</article-title><source>Cells</source><volume>8</volume><elocation-id>728</elocation-id><pub-id pub-id-type="doi">10.3390/cells8070728</pub-id><pub-id pub-id-type="pmid">31315173</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrosillo</surname><given-names>G</given-names></name><name><surname>Di Venosa</surname><given-names>N</given-names></name><name><surname>Ruggiero</surname><given-names>FM</given-names></name><name><surname>Pistolese</surname><given-names>M</given-names></name><name><surname>D’Agostino</surname><given-names>D</given-names></name><name><surname>Tiravanti</surname><given-names>E</given-names></name><name><surname>Fiore</surname><given-names>T</given-names></name><name><surname>Paradies</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mitochondrial dysfunction associated with cardiac ischemia/reperfusion can be attenuated by oxygen tension control. Role of oxygen-free radicals and cardiolipin</article-title><source>Biochimica et Biophysica Acta</source><volume>1710</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2005.10.003</pub-id><pub-id pub-id-type="pmid">16325647</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AR</given-names></name><name><surname>Ames</surname><given-names>EG</given-names></name><name><surname>Knierbein</surname><given-names>EN</given-names></name><name><surname>Hannibal</surname><given-names>MC</given-names></name><name><surname>Mackenzie</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Symptom prevalence and genotype-phenotype correlations in patients with TANGO2-related metabolic encephalopathy and arrhythmias (TRMEA)</article-title><source>Pediatric Neurology</source><volume>119</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2021.02.011</pub-id><pub-id pub-id-type="pmid">33845444</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambold</surname><given-names>AS</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Lippincott-Schwartz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fatty acid trafficking in starved cells: regulation by lipid droplet lipolysis, autophagy, and mitochondrial fusion dynamics</article-title><source>Developmental Cell</source><volume>32</volume><fpage>678</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.01.029</pub-id><pub-id pub-id-type="pmid">25752962</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raote</surname><given-names>I</given-names></name><name><surname>Malhotra</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tunnels for protein export from the endoplasmic reticulum</article-title><source>Annual Review of Biochemistry</source><volume>90</volume><fpage>605</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-080120-022017</pub-id><pub-id pub-id-type="pmid">33503381</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandkuhler</surname><given-names>SE</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Meisner</surname><given-names>JK</given-names></name><name><surname>Ghaloul-Gonzalez</surname><given-names>L</given-names></name><name><surname>Beach</surname><given-names>CM</given-names></name><name><surname>Harris</surname><given-names>D</given-names></name><name><surname>de Lonlay</surname><given-names>P</given-names></name><name><surname>Lalani</surname><given-names>SR</given-names></name><name><surname>Miyake</surname><given-names>CY</given-names></name><name><surname>Mackenzie</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>B-complex vitamins for patients with TANGO2-deficiency disorder</article-title><source>Journal of Inherited Metabolic Disease</source><volume>46</volume><fpage>161</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1002/jimd.12585</pub-id><pub-id pub-id-type="pmid">36550018</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schymick</surname><given-names>J</given-names></name><name><surname>Leahy</surname><given-names>P</given-names></name><name><surname>Cowan</surname><given-names>T</given-names></name><name><surname>Ruzhnikov</surname><given-names>MRZ</given-names></name><name><surname>Gates</surname><given-names>R</given-names></name><name><surname>Fernandez</surname><given-names>L</given-names></name><name><surname>Pramanik</surname><given-names>G</given-names></name><name><surname>Yarlagadda</surname><given-names>V</given-names></name><name><surname>Wheeler</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Enns</surname><given-names>GM</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><collab>Undiagnosed Diseases Network</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Variable clinical severity in TANGO2 deficiency: case series and literature review</article-title><source>American Journal of Medical Genetics. Part A</source><volume>188</volume><fpage>473</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.62543</pub-id><pub-id pub-id-type="pmid">34668327</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sies</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reactive oxygen species (ROS) as pleiotropic physiological signalling agents</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>21</volume><fpage>363</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0230-3</pub-id><pub-id pub-id-type="pmid">32231263</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Willoughby</surname><given-names>MM</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Hamza</surname><given-names>I</given-names></name><name><surname>Reddi</surname><given-names>AR</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HRG-9 homologues regulate haem trafficking from haem-enriched compartments</article-title><source>Nature</source><volume>610</volume><fpage>768</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05347-z</pub-id><pub-id pub-id-type="pmid">36261532</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surma</surname><given-names>MA</given-names></name><name><surname>Herzog</surname><given-names>R</given-names></name><name><surname>Vasilj</surname><given-names>A</given-names></name><name><surname>Klose</surname><given-names>C</given-names></name><name><surname>Christinat</surname><given-names>N</given-names></name><name><surname>Morin-Rivron</surname><given-names>D</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Masoodi</surname><given-names>M</given-names></name><name><surname>Sampaio</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An automated shotgun lipidomics platform for high throughput, comprehensive, and quantitative analysis of blood plasma intact lipids</article-title><source>European Journal of Lipid Science and Technology</source><volume>117</volume><fpage>1540</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1002/ejlt.201500145</pub-id><pub-id pub-id-type="pmid">26494980</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surma</surname><given-names>MA</given-names></name><name><surname>Gerl</surname><given-names>MJ</given-names></name><name><surname>Herzog</surname><given-names>R</given-names></name><name><surname>Helppi</surname><given-names>J</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Klose</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mouse lipidomics reveals inherent flexibility of a mammalian lipidome</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>19364</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-98702-5</pub-id><pub-id pub-id-type="pmid">34588529</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandon</surname><given-names>N</given-names></name><name><surname>Thakkar</surname><given-names>KN</given-names></name><name><surname>LaGory</surname><given-names>EL</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Generation of stable expression mammalian cell lines using lentivirus</article-title><source>Bio-Protocol</source><volume>8</volume><elocation-id>e3073</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.3073</pub-id><pub-id pub-id-type="pmid">30505888</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Vignoli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>TANGO2</data-title><version designator="swh:1:rev:55ba6174b2360f96766315fc87443693352c63f6">swh:1:rev:55ba6174b2360f96766315fc87443693352c63f6</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:88235ddb15742786f872d677e506258cae263e93;origin=https://github.com/alessiovignoli/TANGO2;visit=swh:1:snp:2f4c11a00919e39439149754dd53fed2c25f4124;anchor=swh:1:rev:55ba6174b2360f96766315fc87443693352c63f6">https://archive.softwareheritage.org/swh:1:dir:88235ddb15742786f872d677e506258cae263e93;origin=https://github.com/alessiovignoli/TANGO2;visit=swh:1:snp:2f4c11a00919e39439149754dd53fed2c25f4124;anchor=swh:1:rev:55ba6174b2360f96766315fc87443693352c63f6</ext-link></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85345.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.11.05.515282" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.05.515282"/></front-stub><body><p>This important manuscript describes a series of cellular phenotypes associated with the depletion of TANGO2, a poorly characterized gene product but relevant to neurological and muscular disorders. The authors present solid data indicating that TANGO2 associates with membrane-bound organelles, mainly mitochondria, impacting lipid metabolism and the accumulation of reactive oxygen species.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85345.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pfeffer</surname><given-names>Suzanne R</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.05.515282">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.11.05.515282v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Defects in lipid homeostasis reflect the function of TANGO2 in acyl-CoA metabolism&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Suzanne Pfeffer as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. If possible, please analyze the localization of endogenous TANGO2 by immunofluorescence using the antibody described in Figure S2. The idea that TANGO2 localizes to membrane contact sites between mitochondria and the ER and LDs would also be strengthened by experiments including multiple organelle markers and/or methods to enhance the detection of membrane contact sites [https://doi.org/10.1073/pnas.1910854117].</p><p>2. Please display the absolute levels of all lipids in the various conditions.</p><p>3. RNAi-depletion of Tango2 causes LD accumulation, but it is unclear whether this is due to decreased LD lipolysis, increased LD biogenesis, or some combination of both. Pulse-chase 14C-palmitate experiments (or heavy label palmitate with mass spec) would substantially help the work and would also help determine if rates of acyl-CoA incorporation/turnover into phospholipids are defective in tango2-RNAi cells.</p><p>4. Check whether Tango2 loss impacts AGPAT, LPAAT, and Lipin enzyme levels and/or transcription.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Below are additional specific comments/suggestions that may help improve the manuscript.</p><p>1. The accumulation of lysoPA in Tango2-depleted cells may suggest a defect in AGPAT enzymes, involved in LysoPA acylation. I wonder if the expression levels and/or localization of AGPATs are altered by TANGO2 depletion.</p><p>2. Is the accumulation of reactive-oxygen species related to the lipid defects observed upon TANGO2 depletion? How? Do these cells have increased lipid peroxidation? This analysis may fall outside of the scope of this study but it would be important to discuss the potential links between the ROS and lipid changes.</p><p>3. Figure legends should be improved and include additional information. For example, in Figure 1A only a portion of the amino acid sequence is shown and the residue number should be included. Also, it is unclear what BAD/AVG/GOOD refers to.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This is an interesting study that adds significantly to our understanding of Tango2, a poorly characterized protein linked to muscular disease. Strengths include good use of cell biology and lipidomic analysis to profile tango2-depleted cells. A general concern is that while changes to lyso-lipids are observed, there is not yet a mechanistic understanding of these changes in tango2-depleted cells. Several intriguing models are proposed, but additional experiments are necessary to test these ideas. As noted below, there are also several sections that overstate their conclusions based on present data. Additional experiments should be conducted, or the conclusions toned down. Specific suggestions are below:</p><p>1. The authors note that the EGFP-tagged Tango2 localizes to both mitochondrial and the cytoplasm. Western blotting indicates the construct is not degraded, so they state &quot;it is reasonable to conclude that the transmembrane-domain lacking TANGO2 is attached predominantly to the mitochondrial outer membrane…&quot; This is an over-interpretation. The construct is being stable over-expressed, and the partial cytoplasmic localization may simply be due to overwhelming the mitochondrial import machinery. Further, investigate the topology of Tango 2 and/or tone down the conclusion.</p><p>2. RNAi-depletion of Tango2 causes LD accumulation, but it is unclear whether this is due to decreased LD lipolysis, increased LD biogenesis, or some combination of both. A possibility is the LD accumulation is due to enhanced conversion of PA to DAG, which can be used to make TAG in LDs. Lipidomics suggests a decrease in PA and accumulation of its precursor LPA, as well as changes/decreases in several other mature di-acyl lipids like ceramide. The overall model presented is that LPA and LPG are shunted into cardiolipin synthesis for mitochondrial, resulting in reduced steady-state PA levels. This is an intriguing model, but the data presented are not sufficient to demonstrate it. Additional radio-label or similar approaches to track lipogenesis and PA synthesis/turnover would substantially enhance this study. Since the study suggests a defect in fatty acyl-CoA metabolism, pulse-chase 14C-palmitate experiments would substantially help the work. 14C-palmitate tracking would also help determine if rates of acyl-CoA incorporation/turnover into phospholipids are defective in tango2-RNAi cells.</p><p>3. In overall model suggests lyso-lipids and enriched due to a defect in their acylation. This is done by LPAAT enzymes. Some work to examine whether Tango2 loss impacts LPAAT enzyme levels and/or transcription would help this study.</p><p>4. Similar to the above, the reduced PA levels in Tango2-depleted cells could be due to enhanced Lipin-mediated PA turnover into DAG. This DAG pool would then make TAG and more LDs, as observed. Examining Lipin expression/activity in Tango2-depleted cells would test this. Likewise, Lipin depletion may actually rescue some of the pathology of Tango2-depleted cells.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85345.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. If possible, please analyze the localization of endogenous TANGO2 by immunofluorescence using the antibody described in Figure S2.</p></disp-quote><p>We did not use commercial antibodies to analyze the endogenous localization of TANGO2 because, to our knowledge, no commercial antibodies for immunofluorescence (IF) have been developed. Please see the following table for the data on the commercial preparations used for detecting TANGO2. IHC stands for immunohistochemistry.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><table frame="hsides" rules="groups"><thead><tr><th>Company</th><th>Antibody</th><th>Host</th><th>Clonality</th><th>Immunogen sequence</th><th>Applications</th></tr></thead><tbody><tr><td align="left" valign="top">Merck</td><td align="left" valign="top">Anti-<break/>TANGO2 antibody</td><td align="left" valign="top">Rabbit</td><td align="left" valign="top">Polyclonal</td><td align="left" valign="top">TPVNVQRREDSATEGSHR<break/>LILAANRDEFYSRPSKLADF<break/>WGNNNEILSGLDMEEGKE<break/>GGTWLGISTRGKLAALTNY<break/>LQPQLDWQARGRGELVTH<break/>FLTTDVDSLSYLKKVSMEG<break/>HLYNGFNLIAADLSTAKGD VICYYGNRGEPDPIVLT</td><td align="left" valign="top">IHC</td></tr><tr><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">TANGO2<break/>Polyclonal<break/>Antibody</td><td align="left" valign="top">Rabbit</td><td align="left" valign="top">Polyclonal</td><td align="left" valign="top">TPVNVQRREDSATEGSHR<break/>LILAANRDEFYSRPSKLADF<break/>WGNNNEILSGLDMEEGKE<break/>GGTWLGISTRGKLAALTNY<break/>LQPQLDWQARGRGELVTHF<break/>LTTDVDSLSYLKKVSMEGH<break/>LYNGFNLIAADLSTAKGD<break/>VICYYGNRGEPDPIVLT</td><td align="left" valign="top">IHC</td></tr><tr><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">TANGO2<break/>Polyclonal<break/>Antibody</td><td align="left" valign="top">Rabbit</td><td align="left" valign="top">Polyclonal</td><td align="left" valign="top">Synthetic peptide directed towards the middle region of<break/>human TANGO2</td><td align="left" valign="top">WB</td></tr><tr><td align="left" valign="top">Bioss</td><td align="left" valign="top">C22orf25<break/>Polyclonal<break/>Antibody</td><td align="left" valign="top">Rabbit</td><td align="left" valign="top">Polyclonal</td><td align="left" valign="top">KLH conjugated synthetic peptide derived from human C22orf25, amino acids 25-75.</td><td align="left" valign="top">IHC, WB</td></tr><tr><td align="left" valign="top">OriGene</td><td align="left" valign="top">C22orf25<break/>(TANGO2) Polyclonal<break/>Antibody</td><td align="left" valign="top">Rabbit</td><td align="left" valign="top">Polyclonal</td><td align="left" valign="top">MCIIFFKFDPRPVSKNAYR<break/>LILAANRDEFYSRPSKLADF<break/>WGNNNEILSGL</td><td align="left" valign="top">WB</td></tr><tr><td align="left" valign="top">Novus<break/>Biologicals</td><td align="left" valign="top">TANGO2<break/>Antibody</td><td align="left" valign="top">Rabbit</td><td align="left" valign="top">Polyclonal</td><td align="left" valign="top">MCIIFFKFDPRPVSKNAYR<break/>LILAANRDEFYSRPSKLADF<break/>WGNNNEILSGL</td><td align="left" valign="top">WB</td></tr></tbody></table></table-wrap><p>The commercial antibody we use to determine the presence of TANGO2 by western blot is produced by Novus Biologicals.</p><disp-quote content-type="editor-comment"><p>The idea that TANGO2 localizes to membrane contact sites between mitochondria and the ER and LDs would also be strengthened by experiments including multiple organelle markers and/or methods to enhance the detection of membrane contact sites [https://doi.org/10.1073/pnas.1910854117].</p></disp-quote><p>We have addressed these concerns by the following two independent methods</p><p>1. FRET-based analysis of TANGO2 with Tom20 protein of the mitochondria (Figure 2)</p><p>2. Imaging TANGO2 location in fixed cells with specific ER and LDs proteins in all confocal planes (XY, XZ, and YZ) (Figure 2 and Figure 2—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>2. Please display the absolute levels of all lipids in the various conditions.</p></disp-quote><p>Done (Figure 4—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>3. RNAi-depletion of Tango2 causes LD accumulation, but it is unclear whether this is due to decreased LD lipolysis, increased LD biogenesis, or some combination of both. Pulse-chase 14C-palmitate experiments (or heavy label palmitate with mass spec) would substantially help the work and would also help determine if rates of acyl-CoA incorporation/turnover into phospholipids are defective in tango2-RNAi cells.</p></disp-quote><p>We performed many experiments with 14Cpalmitate pulse-chase t, but the assays were not sensitive to obtain any meaningful data. We then analyzed LD biogenesis and lipolysis using diethylumbelliferyl phosphate (DEUP) in control and starved conditions by flow cytometry (as described in doi:10.1016/j.cub.2013.06.032). We now explain this in the paper. As shown in Figure 3 (new panels H and I), TANGO2-depleted fibroblasts from TDD donors are altered in LD lipolysis and biogenesis.</p><disp-quote content-type="editor-comment"><p>4. Check whether Tango2 loss impacts AGPAT, LPAAT, and Lipin enzyme levels and/or transcription.</p></disp-quote><p>As both reviewers suggested, we measured mRNA levels of all GPAT, AGPAT, and LIPIN isoforms in Mock and TANGO2-depleted cells in control and starvation medium by RT-qPCR.The data are included in the paper.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Below are additional specific comments/suggestions that may help improve the manuscript.</p><p>1. The accumulation of lysoPA in Tango2-depleted cells may suggest a defect in AGPAT enzymes, involved in LysoPA acylation. I wonder if the expression levels and/or localization of AGPATs are altered by TANGO2 depletion.</p></disp-quote><p>We monitored the mRNA levels of AGPAT1-5 in Mock and TANGO2-depleted cells in the control and starvation medium by RT-qPCR. As shown in Figure 5, the mRNA levels of AGPAT1, AGPT2, AGPT3, and AGPT5 are altered in TANGO2-depleted cells. We have explained the significance of these changes in the paper. This is likely a feedback mechanism to maintain the levels of PA. But in cells lacking TANGO2, this signaling method is lost, which further adds to the overall problem of lipid homeostasis.</p><disp-quote content-type="editor-comment"><p>2. Is the accumulation of reactive-oxygen species related to the lipid defects observed upon TANGO2 depletion? How? Do these cells have increased lipid peroxidation? This analysis may fall outside of the scope of this study but it would be important to discuss the potential links between the ROS and lipid changes.</p></disp-quote><p>Good suggestion. We measured total lipid peroxidation in TANGO2-depleted HepG2 cells and human fibroblasts from TDD patients. As shown in the new panels (F-H) of Figure 6, lipid peroxidation increases in cells lacking TANGO2 compared to control cells. These results are now explained in the paper.</p><disp-quote content-type="editor-comment"><p>3. Figure legends should be improved and include additional information. For example, in Figure 1A only a portion of the amino acid sequence is shown and the residue number should be included. Also, it is unclear what BAD/AVG/GOOD refers to.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>This is an interesting study that adds significantly to our understanding of Tango2, a poorly characterized protein linked to muscular disease. Strengths include good use of cell biology and lipidomic analysis to profile tango2-depleted cells. A general concern is that while changes to lyso-lipids are observed, there is not yet a mechanistic understanding of these changes in tango2-depleted cells. Several intriguing models are proposed, but additional experiments are necessary to test these ideas. As noted below, there are also several sections that overstate their conclusions based on present data. Additional experiments should be conducted, or the conclusions toned down. Specific suggestions are below:</p></disp-quote><p>We thank you for your support and suggestions.</p><disp-quote content-type="editor-comment"><p>1. The authors note that the EGFP-tagged Tango2 localizes to both mitochondrial and the cytoplasm. Western blotting indicates the construct is not degraded, so they state &quot;it is reasonable to conclude that the transmembrane-domain lacking TANGO2 is attached predominantly to the mitochondrial outer membrane…&quot; This is an over-interpretation. The construct is being stable over-expressed, and the partial cytoplasmic localization may simply be due to overwhelming the mitochondrial import machinery. Further, investigate the topology of Tango 2 and/or tone down the conclusion.</p></disp-quote><p>We now include data on the topology of TANGO2 by Förster resonance energy transfer (FRET) microscopy. Based on our data, we can confidently state that TANGO2 and Tom20 of the mitochondrial membrane ranges are within 1 -10 nm of each other (Figure 2 panels B-D). We still detect a cytoplasmic pool and how this protein is both at the mitochondrial outer membrane and the cytoplasm remains untested.</p><disp-quote content-type="editor-comment"><p>2. RNAi-depletion of Tango2 causes LD accumulation, but it is unclear whether this is due to decreased LD lipolysis, increased LD biogenesis, or some combination of both. A possibility is the LD accumulation is due to enhanced conversion of PA to DAG, which can be used to make TAG in LDs. Lipidomics suggests a decrease in PA and accumulation of its precursor LPA, as well as changes/decreases in several other mature di-acyl lipids like ceramide. The overall model presented is that LPA and LPG are shunted into cardiolipin synthesis for mitochondrial, resulting in reduced steady-state PA levels. This is an intriguing model, but the data presented are not sufficient to demonstrate it. Additional radio-label or similar approaches to track lipogenesis and PA synthesis/turnover would substantially enhance this study. Since the study suggests a defect in fatty acyl-CoA metabolism, pulse-chase 14C-palmitate experiments would substantially help the work. 14C-palmitate tracking would also help determine if rates of acyl-CoA incorporation/turnover into phospholipids are defective in tango2-RNAi cells.</p></disp-quote><p>We have analyzed the LD biogenesis and lipolysis using diethylumbelliferyl phosphate (DEUP) in control and starved conditions by flow cytometry (as previously described in doi:10.1016/j.cub.2013.06.032). As shown in Figure 3 (new panels H and I), TANGO2-depleted fibroblasts from TDD donors are defective in both LD lipolysis and biogenesis.</p><disp-quote content-type="editor-comment"><p>3. In overall model suggests lyso-lipids and enriched due to a defect in their acylation. This is done by LPAAT enzymes. Some work to examine whether Tango2 loss impacts LPAAT enzyme levels and/or transcription would help this study.</p></disp-quote><p>We measured the mRNA levels of all LPAAT/AGPAT isoforms (1-5) in Mock and TANGO2depleted cells cultured in control and starvation medium by RT-qPCR. As shown in Figure 5, the mRNA levels of AGPAT1, AGPT2, AGPT3, and AGPT5 are altered in TANGO2-depleted cells. The data are explained in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4. Similar to the above, the reduced PA levels in Tango2-depleted cells could be due to enhanced Lipin-mediated PA turnover into DAG. This DAG pool would then make TAG and more LDs, as observed. Examining Lipin expression/activity in Tango2-depleted cells would test this. Likewise, Lipin depletion may actually rescue some of the pathology of Tango2-depleted cells.</p></disp-quote><p>We measured the mRNA levels of LIPIN1-4 in Mock and TANGO2-depleted cells cultured in control and starvation medium by RT-qPCR. As shown in Figure 5, the mRNA levels of LIPIN1-4 didn't have significant alterations in TANGO2-depleted cells. The data are included and explained in the revised manuscript.</p></body></sub-article></article>